<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for preventing typhoid fever - Milligan, R - 2018 | Cochrane Library</title> <meta content="Vaccines for preventing typhoid fever - Milligan, R - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001261.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for preventing typhoid fever - Milligan, R - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001261.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001261.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for preventing typhoid fever" name="citation_title"/> <meta content="Rachael Milligan" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Rachael.Milligan@lstmed.ac.uk" name="citation_author_email"/> <meta content="Mical Paul" name="citation_author"/> <meta content="Rambam Health Care Campus" name="citation_author_institution"/> <meta content="Marty Richardson" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Ami Neuberger" name="citation_author"/> <meta content="Rambam Health Care Campus and The Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD001261.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001261.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001261.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001261.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Incidence; Randomized Controlled Trials as Topic; Salmonella typhi [immunology]; Time Factors; Typhoid Fever [epidemiology, immunology, *prevention &amp; control]; Typhoid‐Paratyphoid Vaccines [adverse effects, *therapeutic use]; Vaccines, Attenuated [adverse effects, therapeutic use]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001261.pub4&amp;doi=10.1002/14651858.CD001261.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001261\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001261\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","th","fa","zh_HANT"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD001261.pub4",title:"Vaccines for preventing typhoid fever",firstPublishedDate:"May 31, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001261.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001261.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001261.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001261.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001261.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001261.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001261.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001261.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001261.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001261.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14288 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001261.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0037"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0038"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0051"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0052"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-sec-0112"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/appendices#CD001261-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/table_n/CD001261StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/table_n/CD001261StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for preventing typhoid fever</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#CD001261-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rachael Milligan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#CD001261-cr-0003">Mical Paul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#CD001261-cr-0004">Marty Richardson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information#CD001261-cr-0005">Ami Neuberger</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information/en#CD001261-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001261.pub4">https://doi.org/10.1002/14651858.CD001261.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001261-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001261-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001261-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001261-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001261-abs-0001" lang="en"> <section id="CD001261-sec-0001"> <h3 class="title" id="CD001261-sec-0001">Background</h3> <p>Typhoid fever and paratyphoid fever continue to be important causes of illness and death, particularly among children and adolescents in south‐central and southeast Asia. Two typhoid vaccines are widely available, Ty21a (oral) and Vi polysaccharide (parenteral). Newer typhoid conjugate vaccines are at varying stages of development and use. The World Health Organization has recently recommended a Vi tetanus toxoid (Vi‐TT) conjugate vaccine, Typbar‐TCV, as the preferred vaccine for all ages. </p> </section> <section id="CD001261-sec-0002"> <h3 class="title" id="CD001261-sec-0002">Objectives</h3> <p>To assess the effects of vaccines for preventing typhoid fever.</p> </section> <section id="CD001261-sec-0003"> <h3 class="title" id="CD001261-sec-0003">Search methods</h3> <p>In February 2018, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and <i>m</i>RCT. We also searched the reference lists of all included trials. </p> </section> <section id="CD001261-sec-0004"> <h3 class="title" id="CD001261-sec-0004">Selection criteria</h3> <p>Randomized and quasi‐randomized controlled trials (RCTs) comparing typhoid fever vaccines with other typhoid fever vaccines or with an inactive agent (placebo or vaccine for a different disease) in adults and children. Human challenge studies were not eligible. </p> </section> <section id="CD001261-sec-0005"> <h3 class="title" id="CD001261-sec-0005">Data collection and analysis</h3> <p>Two review authors independently applied inclusion criteria and extracted data, and assessed the certainty of the evidence using the GRADE approach. We computed vaccine efficacy per year of follow‐up and cumulative three‐year efficacy, stratifying for vaccine type and dose. The outcome addressed was typhoid fever, defined as isolation of <i>Salmonella enterica</i> serovar Typhi in blood. We calculated risk ratios (RRs) and efficacy (1 − RR as a percentage) with 95% confidence intervals (CIs). </p> </section> <section id="CD001261-sec-0006"> <h3 class="title" id="CD001261-sec-0006">Main results</h3> <p>In total, 18 RCTs contributed to the quantitative analysis in this review: 13 evaluated efficacy (Ty21a: 5 trials; Vi polysaccharide: 6 trials; Vi‐rEPA: 1 trial; Vi‐TT: 1 trial), and 9 reported on adverse events. All trials but one took place in typhoid‐endemic countries. There was no information on vaccination in adults aged over 55 years of age, pregnant women, or travellers. Only one trial included data on children under two years of age. </p> <p><b>Ty21a vaccine (oral vaccine, three doses)</b> </p> <p>A three‐dose schedule of Ty21a vaccine probably prevents around half of typhoid cases during the first three years after vaccination (cumulative efficacy 2.5 to 3 years: 50%, 95% CI 35% to 61%, 4 trials, 235,239 participants, moderate‐certainty evidence). These data include patients aged 3 to 44 years. </p> <p>Compared with placebo, this vaccine probably does not cause more vomiting, diarrhoea, nausea or abdominal pain (2 trials, 2066 participants; moderate‐certainty evidence), headache, or rash (1 trial, 1190 participants; moderate‐certainty evidence); however, fever (2 trials, 2066 participants; moderate‐certainty evidence) is probably more common following vaccination. </p> <p><b>Vi polysaccharide vaccine (injection, one dose)</b> </p> <p>A single dose of Vi polysaccharide vaccine prevents around two‐thirds of typhoid cases in the first year after vaccination (year 1: 69%, 95% CI 63% to 74%; 3 trials, 99,979 participants; high‐certainty evidence). In year 2, trial results were more variable, with the vaccine probably preventing between 45% and 69% of typhoid cases (year 2: 59%, 95% CI 45% to 69%; 4 trials, 194,969 participants; moderate‐certainty evidence). These data included participants aged 2 to 55 years of age.The three‐year cumulative efficacy of the vaccine may be around 55% (95% CI 30% to 70%; 11,384 participants, 1 trial; low‐certainty evidence). These data came from a single trial conducted in South Africa in the 1980s in participants aged 5 to 15 years. </p> <p>Compared with placebo, this vaccine probably did not increase the incidence of fever (3 trials, 132,261 participants; moderate‐certainty evidence) or erythema (3 trials, 132,261 participants; low‐certainty evidence); however, swelling (3 trials, 1767 participants; moderate‐certainty evidence) and pain at the injection site (1 trial, 667 participants; moderate‐certainty evidence) were more common in the vaccine group. </p> <p><b>Vi‐rEPA vaccine (two doses)</b> </p> <p>Administration of two doses of the Vi‐rEPA vaccine probably prevents between 50% and 96% of typhoid cases during the first two years after vaccination (year 1: 94%, 95% CI 75% to 99%; year 2: 87%, 95% CI 56% to 96%, 1 trial, 12,008 participants; moderate‐certainty evidence). These data came from a single trial with children two to five years of age conducted in Vietnam. </p> <p>Compared with placebo, both the first and the second dose of this vaccine increased the risk of fever (1 trial, 12,008 and 11,091 participants, low‐certainty evidence) and the second dose increase the incidence of swelling at the injection site (one trial, 11,091 participants, moderate‐certainty evidence). </p> <p><b>Vi‐TT vaccine (two doses)</b> </p> <p>We are uncertain of the efficacy of administration of two doses of Vi‐TT (PedaTyph) in typhoid cases in children during the first year after vaccination (year 1: 94%, 95% CI −1% to 100%, 1 trial, 1625 participants; very low‐certainty evidence). These data come from a single cluster‐randomized trial in children aged six months to 12 years and conducted in India. For single dose Vi‐TT (Typbar‐TCV), we found no efficacy trials evaluating the vaccine with natural exposure. </p> <p>There were no reported serious adverse effects in RCTs of any of the vaccines studied.</p> </section> <section id="CD001261-sec-0007"> <h3 class="title" id="CD001261-sec-0007">Authors' conclusions</h3> <p>The licensed Ty21a and Vi polysaccharide vaccines are efficacious in adults and children older than two years in endemic countries. The Vi‐rEPA vaccine is just as efficacious, although data is only available for children. The new Vi‐TT vaccine (PedaTyph) requires further evaluation to determine if it provides protection against typhoid fever. At the time of writing, there were only efficacy data from a human challenge setting in adults on the Vi‐TT vaccine (Tybar), which clearly justify the ongoing field trials to evaluate vaccine efficacy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001261-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001261-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001261-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001261-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001261-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001261-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001261-abs-0013">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001261-abs-0004" lang="en"> <h3>Vaccines for preventing typhoid fever</h3> <p><b>What was studied in this review?</b> </p> <p>Typhoid fever is a bacterial infection found mainly among children and adolescents in southern and eastern Asia, Africa, Latin America, and the Caribbean. Typhoid fever spreads through contaminated food, drink, or water. It is usually characterized initially by fever, headache, and abdominal symptoms, although other non‐specific symptoms may be present. The infection also sometimes causes confusion or psychosis. In late stages of the infection, intestinal perforation or massive intestinal haemorrhage may occur. Treatment normally consists of antibiotics, but problems with drug‐resistant bacteria strains have been reported. Improved sanitation and food hygiene are important control measures. However, these are associated with socioeconomic progress that has been slow in most affected areas. Therefore vaccination is an effective way to try to prevent this disease. </p> <p><b>What are the main results?</b> </p> <p>We found 18 relevant trials that evaluated four vaccines: 9 reported on vaccine effectiveness only, 4 reported on effectiveness and side effects, and 5 reported on side effects only (we could not analyse one additional trial on adverse events that met the inclusion criteria as it did not provide enough information). The two main vaccines currently licensed for use, Ty21a and Vi polysaccharide, were effective in reducing typhoid fever in adults and children over two years in endemic countries; adverse events such as nausea, vomiting, and fever were rare. Other vaccines, such as new, modified, conjugated Vi vaccines called Vi‐rEPA and Vi‐TT, are in development. These could be given to infants, which would be helpful as they are probably at higher risk for infection, although further evidence for these vaccines is still needed. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies published up to 14 February 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001261-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-sec-0122">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-sec-0198">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001261-sec-0122"></div> <h3 class="title" id="CD001261-sec-0123">Implications for practice</h3> <section id="CD001261-sec-0123"> <p>Based on the available evidence from natural exposure, the currently licensed Ty21a and Vi polysaccharide vaccines are efficacious for preventing typhoid fever in children aged two years or older and in young adults living in typhoid‐endemic regions. Factors such as costs, availability and convenience of administration may determine which vaccine is chosen for use. </p> <p>We are uncertain of the effects of Vi‐TT on typhoid fever, and further data are needed to assess PedaTyph and Typbar‐TCV efficacy in adults and children evaluated through natural exposure. The recent approval of conjugate typhoid vaccine Typbar‐TCV for use in endemic countries by the WHO and SAGE; together with the formation of the Typhoid Vaccine Acceleration Consortium (TyVAC); results of some seroefficacy studies (<a href="./references#CD001261-bbs2-0075" title="VoyseyM , PollardAJ . Sero‐efficacy of Vi‐polysaccharide tetanus‐toxoid typhoid conjugate vaccine (Typbar‐TCV). Clinical Infectious Diseases 2018 Jan 17 [Epub ahead of print]. [DOI: 10.1093/cid/cix1145] ">Voysey 2018</a>); and the pending results of Typbar‐TCV RCTs currently being conducted in Malawi (<a href="./references#CD001261-bbs2-0085" title="NCT03299426 . Clinical efficacy of typhoid conjugate vaccine (Vi‐TCV) among children age 9 months through 12 years in Blantyre, Malawi [A Phase III Randomized, Double‐Blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine (Vi‐TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi]. clinicaltrials.gov/show/NCT03299426 (first received 3 October 2017). ">NCT03299426</a>), Nepal (<a href="./references#CD001261-bbs2-0084" title="ISRCTN43385161 . TyVAC Nepal: typhoid vaccine study [Assessing the impact of a Vi‐Polysaccharide Conjugate Vaccine in preventing typhoid infection among Nepalese children – a Phase III trial]. isrctn.com/ISRCTN43385161 (first received 20 June 2017). ">ISRCTN43385161</a>), and Bangladesh (<a href="./references#CD001261-bbs2-0083" title="ISRCTN11643110 . TyVAC Bangladesh: Typhoid Vaccine Trial [Assessing the impact of a Vi‐Polysaccharide Conjugate Vaccine in preventing typhoid infection among Bangladeshi children – a Phase IV trial]. isrctn.com/ISRCTN11643110 (first received 5 February 2018). ">ISRCTN11643110</a>), will help establish the firm knowledge base required for the introduction of typhoid conjugate vaccines to endemic countries (<a href="./references#CD001261-bbs2-0060" title="MeiringJE , GibaniM . The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26‐27 October 2016, Oxford, UK. Vaccine2017;35(38):5081‐8. ">Meiring 2017</a>). </p> </section> <h3 class="title" id="CD001261-sec-0124">Implications for research</h3> <section id="CD001261-sec-0124"> <p>An effective typhoid vaccine is still needed for children under two years of age. The new Vi‐TT vaccines are promising; however, at present there was only one trial available, which we judged to have very low certainty‐evidence. Further efficacy data are pending and are likely to change this certainty when available. Neither the Vi polysaccharide vaccine nor the Ty21a vaccine is licensed for children younger than two years of age. Future trials should be sufficiently powered to present results stratified by age group. This would mean that vaccine efficacy in different groups could be analysed and would ensure that vaccine delivery can be targeted appropriately (for example, via a school‐based programme or through the expanded programme of immunization (EPI)). </p> <p>None of the included trials compared different types of vaccines used to prevent typhoid fever. Such future comparisons may be helpful in allowing direct conclusions regarding the relative efficacy of the vaccines, although such evidence would not necessarily promote the introduction of vaccines against typhoid fever to new settings and would require substantial resources. </p> <p>Future trials should conduct analyses suited to their design; cluster‐randomization should be accounted for in sample size calculations and in analyses of results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001261-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001261-sec-0037"></div> <div class="table" id="CD001261-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ty21a vaccine (three doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ty21a vaccination (three doses) versus placebo for typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children aged 5 years of age and older </p> <p><b>Settings</b>: any </p> <p><b>Intervention</b>: oral Ty21a (3 doses) ‐ liquid, enteric capsule, or gelatin capsule </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ty21a (3 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 1</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.55</b> (0.35 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 10,000</b><br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b> (0.29 to 0.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,e</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 10,000</b><br/> (17 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.44</b> (0.25 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,e</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 10,000</b><br/> (15 to 45) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2.5 to 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.50</b> (0.39 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235,239<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,f</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (2 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐ risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 10,000</b><br/> (23 to 38) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The incidence of typhoid in a medium ‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>).The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No serious risk of bias detected.<br/> <sup>b</sup>No serious indirectness detected: studies based in Chile, Indonesia, and Egypt.<br/> <sup>c</sup>No serious inconsistency I<sup>2</sup> = 33%.<br/> <sup>d</sup>Downgraded for imprecision: cluster‐adjusted trials added, estimated ICC = 0.0015 (from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>).<br/> <sup>e</sup>No serious inconsistency, no heterogeneity I<sup>2</sup> = 0%.<br/> <sup>f</sup>There is moderate heterogeneity (I<sup>2</sup> = 50%), which is not explained by stratifying into type of preparation. However, the CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically significant, so we have not downgraded for this. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001261-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults and children of 2 years of age and older<br/> <b>Settings</b> : any<br/> <b>Intervention</b> : Vi polysaccharide vaccine (1 dose)<br/> <b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi polysaccharide vaccine (1 dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 1</b><br/> Blood culture </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.31</b> <br/> (0.26 to 0.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>99,797<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>b,c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.2 per 10,000</b><br/> (1.0 to 1.5) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18.29 per 10,000</b><br/> (15.34 to 21.83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b><br/> (0.31 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>194,969<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,f,g,e</sup> </p> <p>Due to inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.6 per 10,000</b><br/> (1.2 to 2.2) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24.19 per 10,000</b><br/> (18.29 to 32.45) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>I<b>ncidence of typhoid fever</b> –<b>year 3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.5</b> </p> <p>(0.32 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>11,384</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>h,i</sup> </p> <p>Due to imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>May reduce incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b> </p> <p>(1.28 to 3.12)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29.5 per 10,000</b> </p> <p>(18.88 to 46.02)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2.5 to 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> (0.30 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>11,384</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>h,i</sup> </p> <p>Due to imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>May reduce incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.8 per 10,000</b> </p> <p>(1.2 to 2.8)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26.55 per 10,000</b> (17.7 to 41.3) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No serious adverse events reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> <p>(4.2 to 5.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132,261<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,c,k,l</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably little or no association with fever</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (2 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> <br/> (0.33 to 4.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132,261<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>b,j,l</sup> </p> <p>Due to imprecision and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have little or no association with erythema</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>).The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <sup>b</sup>No serious risk of bias detected.<br/> <sup>c</sup>No serious inconsistency: The result was consistent across all 3 trials (I<sup>2</sup> = 0%).<br/> <sup>d</sup>No serious indirectness: the vaccine has been evaluated in trials from Nepal, South Africa and China. Of note, none of the trials were conducted in travellers from nonendemic settings, and all three trials excluded children younger than 2 years of age and pregnant women.<br/> <sup>e</sup>No serious imprecision: the result is statistically significant with a narrow 95% CI. The meta‐analysis is adequately powered to detect this effect.<br/> <sup>f</sup>Downgraded by 1 level for inconsistency: the magnitude of the protective effect varied between trials from 34% to 69% (I<sup>2</sup> = 72%). The reasons for this are not clear; one potential factor may be the different age groups included in the trials, with <a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a> suggesting lower protective effect in children &lt; 5 years of age.<br/> <sup>g</sup>No serious indirectness: the vaccine has been evaluated in trials from endemic settings (India, Pakistan, China and South Africa).<br/> <sup>h</sup>Downgraded by 1 level for imprecision: wide CIs.<br/> <sup>i</sup>Downgraded by 1 level for indirectness ‐ only assessed in one trial in South Africa in children aged 5 to 15 years.<br/> <sup>k</sup>No serious indirectness: the vaccine has been evaluated in trials from endemic settings (China) and in one trial conducted in a non‐endemic setting (USA).<br/> <sup>l</sup>Downgraded by 1 level for serious imprecision: The result is not statistically significant.<br/> <sup>j</sup>Downgraded by 1 level for inconsistency (I<sup>2</sup> = 63%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001261-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults and children of 2 years of age and older<br/> <b>Settings</b> : any<br/> <b>Intervention</b> : Vi‐rEPA vaccine (2 doses)<br/> <b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi‐rEPA vaccine (2 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 1</b><br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.06</b> <br/> (0.01 to 0.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,c</sup> </p> <p>Due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.24 per 10,000</b><br/> (0.04 to 1) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3.5 per 10,000</b><br/> (0.6 to 14.8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.13</b> <br/> (0.04 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.52 per 10,000</b><br/> (0.16 to 1.8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7.7 per 10,000</b><br/> (2.4 to 26.0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.09</b> (0.04 to 0.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.36 per 10,000</b> (0.16 to 0.88) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5.31 per 10,000</b> (2.36 to 12.98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 3.8 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> (0.05 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.44 per 10,000</b> (0.2 to 0.92) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6.49 per 10,000</b> </p> <p>(2.95 to 13.57)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after Vi‐rEPA (dose1)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(8 to 18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.54</b> <br/> (1.69 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with fever following vaccination</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after Vi‐rEPA (dose2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(11 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.39</b> </p> <p>(2.85 to 6.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with fever following vaccination</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema after Vi‐rEPA (dose 2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.4 per 1000</b> </p> <p>(0.04 to 4.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/> (0.19 to 22.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> <p>Due to serious imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have little or no association with erythema</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Swelling at injection site after Vi‐rEPA (dose 2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> <p>(0.5 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 20.15</b> <br/> (2.71 to 150.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with swelling at injection site</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <sup>b</sup>No serious risk of bias detected.<br/> <sup>c</sup>Downgraded by 1 level for indirectness: the vaccine has been evaluated by only one trial in children 2 to 5 years of age in a high‐incidence setting (Vietnam).<br/> <sup>d</sup>Downgraded by 1 level for imprecision: wide 95% CIs.<br/> <sup>e</sup>Downgraded by 1 level for serious imprecision: the result is not statistically significant. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001261-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Vi‐TT conjugate vaccine (PedaTyph) (2 doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi‐TT conjugate vaccine versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children aged 6 months to 12 years </p> <p><b>Settings</b> : India<br/> <b>Intervention</b>: Vi‐TT (PedaTyph) vaccine (2 doses) </p> <p><b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi‐TT conjugate; (2 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of typhoid fever – year 1</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.8 per 1000</p> <p>(0 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.06<sup>b</sup> </p> <p>(0.00 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1625<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d,e</sup> </p> <p>Due to risk of bias, serious imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if this vaccine prevents typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The basis for the assumed risk is taken from the disease incidence in the control group in the trial (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>).<br/> <sup>b</sup>Primary trial is not cluster‐adjusted. This estimate uses a small assumed intracluster correlation coefficient of 0.0015 calculated from cluster‐randomized ViPs vaccine trial <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>, which did adjust for clustering.<br/> <sup>c</sup>Downgraded by 1 level for risk of bias.<br/> <sup>d</sup>Downgraded by 1 level for imprecision. Wide CIs that include appreciable harm and few (11 events) in the trial.<br/> <sup>e</sup>Downgraded by 1 level for indirectness. Only one trial in one setting and in children under 12 years. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001261-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-sec-0038">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-sec-0144">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD001261-sec-0038"></div> <section id="CD001261-sec-0039"> <h3 class="title" id="CD001261-sec-0039">Description of the condition</h3> <section id="CD001261-sec-0040"> <h4 class="title">Epidemiology</h4> <p>Typhoid fever is a systemic infection caused by the Gram‐negative bacterium <i>Salmonella enterica</i> serovar Typhi (<i>S.</i> Typhi). <i>S.</i> Typhi spreads by food, drink, or water contaminated by faecal or urinary carriers excreting the bacteria. Typhoid fever, also called enteric fever, remains an important global public health problem. Estimating disease burden is difficult for a number of reasons, including the poor sensitivity of diagnostic tests and lack of surveillance in countries with suspected high prevalence (<a href="./references#CD001261-bbs2-0086" title="AndrewsJR , RyanET . Diagnostics for invasive Salmonella infections: current challenges and future directions. Vaccine2015;33(3):C8‐15. ">Andrews 2015</a>). In 2010 there were an estimated 20.6 million cases of typhoid fever in low‐ and middle‐income countries, with 223,000 deaths (although after adjusting for risk factors and corrected diagnostic testing, the estimate dropped to 11.9 million cases and 129,000 deaths; <a href="./references#CD001261-bbs2-0105" title="MogasaleV , MaskeryB , OchiaiRL , LeeJS , MogasaleVV , RamaniE , et al. Burden of typhoid fever in low‐income and middle‐income countries: a systematic, literature‐based update with risk‐factor adjustment. Lancet Global Health2014;2(10):e570‐80. ">Mogasale 2014</a>). This lack of robust data makes decision‐making on priorities and resource allocation difficult and may negatively impact investment in typhoid fever (<a href="./references#CD001261-bbs2-0092" title="CrumpJA . Building the case for wider use of typhoid vaccines. Vaccine2015;33(3):C1‐2. ">Crump 2015</a>). </p> <p>The highest burden of typhoid fever is thought to be in South Asia (<a href="./references#CD001261-bbs2-0116" title="WainJ , HendriksenRS , MikoleitML , KeddyKH , OchiaiRL . Typhoid Fever. Lancet2015;385(9973):1136‐45. ">Wain 2015</a>). Typhoid fever incidence in sub‐Saharan Africa has historically been poorly described; but the recent Typhoid Surveillance in Africa programme, funded by the Gates Foundation, has shown that incidence in many African countries may be as high as that in Asia (<a href="./references#CD001261-bbs2-0114" title="SteeleAD , BurgessDC , DiazZ , CareyME , ZaidiAK . Challenges and opportunities for typhoid fever control: a call for coordinated action. Clinical Infectious Diseases2016;62(1):S4‐8. ">Steele 2016</a>). Typhoid fever is rare in industrialized nations, although travellers to endemic countries are at risk of acquiring the disease, with a recent survey naming it the second most common potentially life threatening infectious disease in travellers (<a href="./references#CD001261-bbs2-0098" title="JenseniusM , HanPV , SchlagenhaufP , SchwartzE , ParolaP , CastelliF , et al. Acute and potentially life‐threatening tropical diseases in western travelers—a GeoSentinel multicenter study, 1996–2011. American Journal of Tropical Medicine and Hygiene2013;88(2):397‐404. ">Jensenius 2013</a>). </p> <p>Until recently, the common view was that typhoid fever mainly affects children of school age and adults. However, experts now recognize that typhoid fever is an important cause of morbidity among younger children in areas of high incidence (<a href="./references#CD001261-bbs2-0107" title="OchiaiRL , AcostaCJ , Danovaro‐HollidayMC , BaiqingD , BhattacharyaSK , AgtiniMD , et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bulletin of the World Health Organization2008;86(4):260‐8. ">Ochiai 2008</a>; <a href="./references#CD001261-bbs2-0111" title="SahaSK , BaquiAH , HanifM , DarmstadtGL , RuhulaminM , NagatakeT , et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatric Infectious Disease Journal2001;20(5):521‐4. ">Saha 2001</a>; <a href="./references#CD001261-bbs2-0113" title="SinhaA , SazawalS , KumarR , SoodS , ReddaiahVP , SinghB , et al. Typhoid fever in children aged less than 5 years. Lancet1999;354(9180):734‐7. ">Sinha 1999</a>). </p> </section> <section id="CD001261-sec-0041"> <h4 class="title">Clinical features</h4> <p>After ingestion of <i>S.</i> Typhi or <i>S.</i> Paratyphi, the bacteria spread from the intestine via the blood, where they multiply to the intestinal lymph nodes, liver, and spleen. Typhoid fever is usually characterized initially by fever, headache, and abdominal symptoms, although other nonspecific symptoms may occur. Neuropsychiatric manifestations, including psychosis and confusion, may occur. Other signs include relative bradycardia, rose spots, hepatomegaly, and splenomegaly, although these signs are not pathognomonic (<a href="./references#CD001261-bbs2-0103" title="MandellGL , BennettJE , DolinR , editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th Edition. New York: Elsevier/Churchill Livingstone, 2005. ">Mandell 2005</a>). </p> <p>Complications occur in 10% to 15% of untreated patients, usually in the third and fourth weeks of infection. The most important complications are gastrointestinal bleeding, occurring in up to 10% of patients (<a href="./references#CD001261-bbs2-0108" title="ParryCM , HienTT , DouganG , WhiteNJ , FarrarJJ . Typhoid fever. New England Journal of Medicine2002;347(22):1770‐82. ">Parry 2002</a>), followed by intestinal perforation and typhoid encephalopathy. Estimates of case‐fatality rates in typhoid fever range from 1% to 4%; fatality rates in children younger than 4 years of age are 10 times higher than in older children. In untreated cases, the fatality rates may rise to 10% to 20% (<a href="./references#CD001261-bbs2-0088" title="BhuttaZA . Impact of age and drug resistance on mortality in typhoid fever. Archives of Diseases of Childhood1996;75(3):214‐7. ">Bhutta 1996</a>). </p> <p>Both <i>S.</i> Typhi and <i>S.</i> Paratyphi can cause enteric fever, and the clinical manifestations of these two infections are similar. In some areas enteric fever caused by <i>S.</i> Paratyphi is more common (<a href="./references#CD001261-bbs2-0102" title="MacLennanCA , MartinLB , MicoliF . Vaccines against invasive Salmonella disease: current status and future directions. Human Vaccines &amp; Immunotherapeutics2014;10(6):1478‐93. ">MacLennan 2014</a>). </p> </section> <section id="CD001261-sec-0042"> <h4 class="title">Diagnosis and treatment</h4> <p>Confirmation of typhoid fever requires isolating <i>S.</i> Typhi from blood, bone marrow, stool, or duodenal fluid by culture. The Widal test, which identifies antibodies against <i>S.</i> Typhi antigens in blood, has poor sensitivity overall and poor specificity in endemic areas (<a href="./references#CD001261-bbs2-0087" title="BhanMK , BahlR , BhatnagarS . Typhoid and paratyphoid fever. Lancet2005;366(9487):749‐62. ">Bhan 2005</a>; <a href="./references#CD001261-bbs2-0109" title="QamarFN , AzmatullahA , BhuttaZA . Challenges in measuring complications and death due to invasive Salmonella infections. Vaccine2015;33(3):C16‐20. ">Qamar 2015</a>). New‐generation, rapid, serologic tests have been developed, including a dot enzyme‐linked immunosorbent assay test that detects IgM and IgG antibodies against an outer membrane protein of Salmonella Typhi (Typhidot) and an anti‐O9 IgM antibody specific for group D Salmonellae (Tubex) (<a href="./references#CD001261-bbs2-0101" title="KeddyKH , SookaA , LetsoaloME , HoylandG , ChaignatCL , MorrisseyAB , CrumpJA . Sensitivity and specificity of typhoid fever rapid antibody tests for laboratory diagnosis at two sub‐Saharan African sites. Bulletin of the World Health Organization2011;89(9):640‐7. ">Keddy 2011</a>). However, a recent systemic review found inadequate sensitivity and specificity for these as well (<a href="./references#CD001261-bbs2-0115" title="ThriemerK , LeyB , MentenJ , JacobsJ , van denEndeJ . Review and meta‐analysis of the performance of two point of care typhoid fever tests, Tubex TF and Typhidot, in endemic countries. PLOS ONE2013;8(12):e81263. ">Thriemer 2013</a>). </p> <p>Effective and early treatment with antibiotics shortens disease course and reduces the risk of complications (<a href="./references#CD001261-bbs2-0100" title="KariukiS , GordonMA , FeaseyN , ParryCM . Antimicrobial resistance and management of invasive Salmonella disease. Vaccine2015;33(3):C21‐9. ">Kariuki 2015</a>). A multi‐drug resistant (MDR) strain of <i>S.</i> Typhi to chloramphenicol, ampicillin and co‐trimoxazole emerged in the late 1980s in Asia, and later in Africa. This has declined with widespread use of fluoroquinolones. Unfortunatley, <i>S.</i> Typhi strains with reduced sensitivity and resistance to fluoroquinolones developed in the 1990s, mainly in the Indian subcontinent (<a href="./references#CD001261-bbs2-0116" title="WainJ , HendriksenRS , MikoleitML , KeddyKH , OchiaiRL . Typhoid Fever. Lancet2015;385(9973):1136‐45. ">Wain 2015</a>). Third generation cephalosporins (such as ceftriaxone and cefotaxime) are often used, particularly in patients admitted to hospital. Sporadic reports of emerging resistance to these antibiotics is of serious concern (<a href="./references#CD001261-bbs2-0100" title="KariukiS , GordonMA , FeaseyN , ParryCM . Antimicrobial resistance and management of invasive Salmonella disease. Vaccine2015;33(3):C21‐9. ">Kariuki 2015</a>). Azithromicyn is being used increasingly as a first‐line oral treatment option. </p> </section> <section id="CD001261-sec-0043"> <h4 class="title">Potential control measures</h4> <p>Given the route of transmission and the fact that humans are the only source of infection, improved sanitation and food hygiene are important control measures. However, these measures are associated with socioeconomic progress, which has been slow in most endemic areas. Furthermore, achieving control of typhoid fever by antimicrobial treatment alone requires well‐functioning medical services and is hindered by the increasing problem of antibiotic‐resistant <i>S.</i> Typhi<i>.</i> Therefore vaccination against typhoid fever is a key control measure in high‐risk areas (<a href="./references#CD001261-bbs2-0119" title="World Health Organization. Typhoid vaccine: WHO position paper. Weekly Epidemiological Record2008;83(6):49‐60. ">WHO 2008</a>). In addition to the populations residing in areas in which typhoid fever is endemic, travellers to these regions as well as household contacts of typhoid fever carriers and laboratory workers may benefit from an effective vaccine (<a href="./references#CD001261-bbs2-0108" title="ParryCM , HienTT , DouganG , WhiteNJ , FarrarJJ . Typhoid fever. New England Journal of Medicine2002;347(22):1770‐82. ">Parry 2002</a>). </p> </section> </section> <section id="CD001261-sec-0044"> <h3 class="title" id="CD001261-sec-0044">Description of the intervention</h3> <p>Vaccination against typhoid fever is a key control measure; however, despite their evaluation in populations in endemic low‐ and middle‐ income countries, travellers from high‐income countries are the primary users of typhoid fever vaccines. This situation is changing, thanks to the availability of high‐quality burden of disease data from endemic countries (<a href="./references#CD001261-bbs2-0107" title="OchiaiRL , AcostaCJ , Danovaro‐HollidayMC , BaiqingD , BhattacharyaSK , AgtiniMD , et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bulletin of the World Health Organization2008;86(4):260‐8. ">Ochiai 2008</a>); to the experience of typhoid vaccination programmes in Thailand, China, Vietnam, and India (<a href="./references#CD001261-bbs2-0094" title="DeroeckD , OchiaiL , YangJ , AnhD , AlagV , ClemensJ . Typhoid vaccination: the Asian experience. Expert Review of Vaccines2008;7(5):547‐60. ">DeRoeck 2008</a>); and to vaccine demonstration projects in five Asian countries (<a href="./references#CD001261-bbs2-0106" title="OchiaiL , AcostaC , AgtiniM , BhattacharyaS , BhuttaZ , DoC , et al. The use of typhoid vaccines in Asia: the DOMI experience. Clinical Infectious Diseases2007;45(Suppl 1):S34‐38. ">Ochiai 2007</a>). A 2008 World Health Organization (WHO) position paper on the use of typhoid vaccines concluded that given the continued high burden of disease and increasing antibiotic resistance, countries should consider the programmatic use of typhoid vaccines for controlling endemic disease (<a href="./references#CD001261-bbs2-0119" title="World Health Organization. Typhoid vaccine: WHO position paper. Weekly Epidemiological Record2008;83(6):49‐60. ">WHO 2008</a>). Despite this recommendation, very few typhoid endemic countries have implemented a typhoid vaccination programme (<a href="./references#CD001261-bbs2-0104" title="MauriceJ . A first step in bringing typhoid fever out of the closet. Lancet2012;379(9817):699‐700. ">Maurice 2012</a>). Up until recently, there were no typhoid vaccines effective for children younger than two years, who carry a large disease burden in developing countries. More recently, newer typhoid conjugate vaccines (TCV) have entered use, with evidence of immunogenicity in children from six months old. These show a potential for inclusion in the infant expanded programme on immunization (<a href="./references#CD001261-bbs2-0093" title="DateKA , Bentsi‐EnchillA , MarksF , FoxK . Typhoid fever vaccination strategies. Vaccine2015;33(3):C55‐61. ">Date 2015</a>). </p> <p>The following typhoid vaccines have been developed.</p> <section id="CD001261-sec-0045"> <h4 class="title">Inactivated whole‐cell typhoid vaccine</h4> <p>Although vaccines of this type were introduced in 1896 (<a href="./references#CD001261-bbs2-0118" title="Initiative for Vaccines Research, World Health Organization. Diarrhoeal diseases. State of the Art of Vaccine Research and Development. Geneva: World Health Organization, 2005. ">WHO 2005</a>), their efficacy was established only in 1960 in controlled trials in Yugoslavia, the Soviet Union, Poland, and Guyana. The 1998 version of this Cochrane Review demonstrated that two doses of this type of vaccine resulted in 73% efficacy over three years (95% confidence interval (CI) 65% to 80%) (<a href="./references#CD001261-bbs2-0124" title="EngelsEA , LauJ . Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews1998, Issue 4. [DOI: 10.1002/14651858.CD001261] ">Engels 1998a</a>). Different methods of inactivating <i>S.</i> Typhi cells have been used to prepare these vaccines: acetone‐inactivated, alcohol‐inactivated or heat‐inactivated and phenol preserved. In field trials, the vaccine has been associated with fever and systemic reactions in 9% to 34% of recipients, and with short absences from work or school in 2% to 17% of cases (<a href="./references#CD001261-bbs2-0117" title="World Health Organization. Typhoid vaccines: WHO position paper. Weekly Epidemiological Record2000;75(32):257‐64. ">WHO 2000</a>). Therefore, the inactivated whole‐cell typhoid vaccine is considered unsuitable for use as a public health vaccine, and, although licensed, it is no longer available for use (<a href="./references#CD001261-bbs2-0095" title="GarmoryHS , BrownKA , TitballRW . Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiology Reviews2002;26(4):339‐53. ">Garmory 2002</a>). Consequently, we have not included killed whole‐cell vaccines in this update. </p> </section> <section id="CD001261-sec-0046"> <h4 class="title">Ty2la vaccine</h4> <p>Ty21a is a live oral vaccine derived from an attenuated strain of <i>S.</i> Typhi, approved for use in children aged six years or older. It is available as an enteric‐coated capsule and is given in three doses (four doses in North America) every other day. The liquid formulation, which was approved in children over two years old, is not currently available (<a href="./references#CD001261-bbs2-0121" title="World Health Organization. Table 1: Summary of WHO position papers ‐ recommendations for routine immunization. cdrwww.who.int/immunization/policy/Immunization_routine_table1.pdf Updated April 2018 (accessed 30 April 2018). ">WHO 2018b</a>). It elicits protection that starts 10 to 14 days after the third dose. Travellers should be revaccinated every three to five years with continued or repeat exposure and those living in disease endemic areas every three years. A theoretical question associated with the Ty21a vaccine is whether it reverts to virulence; however, none of the multiple large field trials conducted have documented such hypothetical effects, which are considered exceptionally unlikely given the degree of attenuation (<a href="./references#CD001261-bbs2-0119" title="World Health Organization. Typhoid vaccine: WHO position paper. Weekly Epidemiological Record2008;83(6):49‐60. ">WHO 2008</a>). </p> </section> <section id="CD001261-sec-0047"> <h4 class="title">M01ZH09 vaccine</h4> <p>A human challenge trial has assessed a new live attenuated oral typhoid vaccine, M01ZH09 (<a href="./references#CD001261-bbs2-0039" title="DartonTC , JonesC , BlohmkeCJ , WaddingtonCS , ZhouL , PetersA , et al. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLOS Neglected Tropical Diseases2016;10(8):e0004926. ">Darton 2016</a>). M01ZH09 is constructed from a parent Ty2 strain. Following vaccination with M01ZH09 or placebo in a double‐blind randomized trial, participants were artificially infected with <i>S.</i> Typhi. A single dose was not found to be effective in preventing infection (RR 1.81, 95% CI 0.66 to 5). However, as this was a human challenge, its clinical effects remain unknown. </p> </section> <section id="CD001261-sec-0048"> <h4 class="title">Vi polysaccharide vaccine</h4> <p>Vi polysaccharide is based on a purified capsular polysaccharide of <i>S.</i> Typhi Vi antigen (<a href="./references#CD001261-bbs2-0093" title="DateKA , Bentsi‐EnchillA , MarksF , FoxK . Typhoid fever vaccination strategies. Vaccine2015;33(3):C55‐61. ">Date 2015</a>). Given in a single parenteral dose, protection begins seven days after injection, with maximum protection achieved at 28 days, when the highest antibody concentration is attained (<a href="./references#CD001261-bbs2-0095" title="GarmoryHS , BrownKA , TitballRW . Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiology Reviews2002;26(4):339‐53. ">Garmory 2002</a>). This vaccine is approved for people aged two years and older. It is not immunogenic in younger children, Revaccination every three years is recommended. </p> </section> <section id="CD001261-sec-0049"> <h4 class="title">Typhoid conjugate vaccines</h4> <p>Typhoid conjugate vaccines (TCV) are injectable subunit vaccines where Vi capsular polysaccharide antigen is linked to a protein carrier (<a href="./references#CD001261-bbs2-0093" title="DateKA , Bentsi‐EnchillA , MarksF , FoxK . Typhoid fever vaccination strategies. Vaccine2015;33(3):C55‐61. ">Date 2015</a>). </p> <p><b>Vi‐rEPA</b>, a modified Vi vaccine conjugated to a nontoxic recombinant <i>Pseudomonas aeruginosa</i> exotoxin A (rEPA), is given as two parenteral doses. Although theoretically immunogenic from six months old, it has only been used in children over two years (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>). This vaccine has not been commercialized. </p> <p><b>Vi‐TT</b> , a new conjugated Vi‐polysaccharide linked to tetanus toxoid carrier protein, has been licensed in India in two preparations: <b>Peda Typh</b> (two doses, children six months and above; <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>) and <b>Typbar‐TCV</b> (one dose, children six months and above; <a href="./references#CD001261-bbs2-0050" title="JinC , GibaniMM , MooreM , JuelHB , JonesE , MeiringJ , et al. Efficacy and immunogenicity of a Vi‐tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet2017;390(10111):2472‐80. ">Jin 2017</a>; <a href="./references#CD001261-bbs2-0061" title="MohanVK , VaranasiV , SinghA , PasettiMF , LevineMM , VenkatesanR , EllaKM . Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar‐TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2‐cohort, open‐label, double‐blind, randomized controlled phase 3 study. Clinical Infectious Diseases2015;61(3):393‐402. ">Mohan 2015</a>). WHO has approved Typbar‐TCV for infants and children over six months of age in endemic areas (<a href="./references#CD001261-bbs2-0120" title="World Health Organization. Tyhoid vaccines: WHO position paper ‐ March 2018. Weekly Epidemiological Record2018; Vol. 93, issue 13:154‐72, Available from: apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1 (last accessed 23 April 2018). ">WHO 2018a</a>). </p> </section> </section> <section id="CD001261-sec-0050"> <h3 class="title" id="CD001261-sec-0050">Why it is important to do this review</h3> <p>This update of the 2014 Cochrane Review, <a href="./references#CD001261-bbs2-0123" title="AnwarE , GoldbergE , FraserA , AcostaCJ , PaulM , LeiboviciL . Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD001261.pub3] ">Anwar 2014</a>, provides an updated assessment of the efficacy and safety of vaccines to prevent typhoid fever by incorporating data from new trials and vaccines and incorporating cluster‐randomized controlled trials in the meta‐analyses. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001261-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-sec-0051">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-sec-0157">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001261-sec-0051"></div> <p>To assess the effects of vaccines for preventing typhoid fever.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001261-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-sec-0052">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-sec-0158">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001261-sec-0052"></div> <section id="CD001261-sec-0053"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001261-sec-0054"> <h4 class="title">Types of studies</h4> <p>Randomized and quasi‐randomized controlled trials.</p> </section> <section id="CD001261-sec-0055"> <h4 class="title">Types of participants</h4> <p>Adults and children.</p> </section> <section id="CD001261-sec-0056"> <h4 class="title">Types of interventions</h4> <section id="CD001261-sec-0057"> <h5 class="title">Intervention</h5> <p>Vaccines against <i>S.</i> Typhi include the following. </p> <p> <ul id="CD001261-list-0001"> <li> <p>Live oral vaccine Ty2la or genetic modifications of this strain.</p> </li> <li> <p>Vi polysaccharide vaccine.</p> </li> <li> <p>Conjugate vaccines.</p> </li> </ul> </p> </section> <section id="CD001261-sec-0058"> <h5 class="title">Control</h5> <p> <ul id="CD001261-list-0002"> <li> <p>No vaccine, placebo or typhoid‐inactive agents (vaccine for a different disease)</p> </li> <li> <p>Other typhoid vaccines</p> </li> </ul> </p> <p>For the secondary outcome of adverse events, we included only placebo‐controlled trials.</p> </section> <section id="CD001261-sec-0059"> <h5 class="title">Excluded interventions</h5> <p>We excluded studies focusing on the following types of interventions.</p> <p> <ul id="CD001261-list-0003"> <li> <p>Trials that evaluated killed whole‐cell vaccines, because these vaccines are no longer in use. </p> </li> <li> <p>Trials that reported only on immunogenicity.</p> </li> <li> <p>Trials that assessed only adverse events but not clinical efficacy of vaccines that have not yet been evaluated for clinical efficacy. </p> </li> <li> <p>Human challenge studies where participants were artificially infected with<i>S.</i> Typhi at a certain time point following vaccination, since the bacterial inoculum in challenge trials is constant and the timing of infection relative to vaccination is highly controlled compared to the real life situation. We therefore believe these trials to be less relevant for clinicians and policy‐making. </p> </li> </ul> </p> </section> </section> <section id="CD001261-sec-0060"> <h4 class="title">Types of outcome measures</h4> <section id="CD001261-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD001261-sec-0062"> <h6 class="title">Typhoid fever</h6> <p>Typhoid fever defined by isolation of <i>S.</i> Typhi from blood cultures. </p> </section> </section> <section id="CD001261-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD001261-sec-0064"> <h6 class="title">Adverse events</h6> <p> <ul id="CD001261-list-0004"> <li> <p>Serious adverse events, defined as leading to death, requiring inpatient hospitalization or prolonged existing hospitalization, life threatening, or resulting in persistent or significant disability or incapacity. </p> </li> <li> <p>Other adverse events, including fever, erythema at injection site, vomiting, and diarrhoea.</p> </li> </ul> </p> <p>When the occurrence of adverse events was reported after each of several doses, we extracted the occurrence following each dose separately. When reports provided estimates of the incidence of adverse events for different time points after vaccination, we presented the data corresponding to 24 hours after vaccination. </p> </section> </section> </section> </section> <section id="CD001261-sec-0065"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD001261-sec-0066"> <h4 class="title">Databases</h4> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD001261-sec-0128">Appendix 1</a>: Cochrane Infectious Diseases Group Specialized Register (searched 14 February 2018); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2018, Issue 2 of 12); MEDLINE (1966 to 14 February 2018); Embase (1974 to 14 February 2018); and LILACS (1982 to 14 February 2018). We also searched the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) using ‘typhoid' and ‘vaccine' as search terms (searched 14 February 2018). We searched the Internet for new drug application (NDA) documents of the US Food and Drug Administration, which may include unpublished studies (last accessed 14 February 2018). </p> </section> <section id="CD001261-sec-0067"> <h4 class="title">Conference proceedings</h4> <p>We searched the following conference proceedings for relevant abstracts: International Conference on Typhoid and other Invasive Salmonelloses (2013 to 2017); Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ASM Microbe; 1995 to 2017); European Congress of Clinical Microbiology and Infectious Diseases (ECCMID; 2001 to 2017); and the Annual Meeting of the Infectious Diseases Society of America (IDSA; 2001 to 2017). </p> </section> <section id="CD001261-sec-0068"> <h4 class="title">Reference lists</h4> <p>We examined the reference lists of the included trials.</p> </section> </section> <section id="CD001261-sec-0069"> <h3 class="title" id="CD001261-sec-0069">Data collection and analysis</h3> <section id="CD001261-sec-0070"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently inspected titles and abstracts identified by the literature search to identify potentially relevant publications, retrieving the full text of any record that at least one review author judged as potentially relevant. We applied the inclusion criteria for the final decision regarding eligibility. We also ascertained that trials were independent, that is, we looked for multiple publications of the same trial and made sure that we included each trial only once. If a single included reference included more than one trial, we labelled the trials separately using a letter (for example, <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> and <a href="./references#CD001261-bbs2-0023" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980b EGY</a>). We resolved disagreements by discussion and consensus, documenting reasons for excluding studies from the review. We attempted to contact trial authors for clarification if it was unclear whether a potentially relevant trial was eligible for the review. </p> </section> <section id="CD001261-sec-0071"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data into a standard form; a third review author extracted the data in cases of disagreement. One review author entered data into RevMan 5 (<a href="./references#CD001261-bbs2-0110" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD001261-sec-0072"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias in included trials; in cases of disagreement, we consulted a third review author. We took an individual component approach to quality assessment by using five variables: generation of allocation sequence; allocation concealment; blinding of participants and investigators; inclusion of all randomly assigned participants in the analysis; and reporting of all stated outcomes. We categorized generation of the allocation sequence and allocation concealment as adequate, unclear, or inadequate by using the approach described in <a href="./references#CD001261-bbs2-0099" title="JüniP , AltmanDG , EggerM . Systematic reviews in healthcare: assessing the quality of controlled trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>. We recorded whether trials used single, double or no blinding, and whether they reported results for all randomized participants. </p> </section> <section id="CD001261-sec-0073"> <h4 class="title">Measures of treatment effect</h4> <p>We recorded the number of participants experiencing the event and the number analysed in each treatment group. We aimed to extract data according to an intention‐to‐treat analysis and reported any discrepancies in the number randomly assigned and the numbers analysed in each treatment group. We calculated risk ratios with 95% CIs, and in cluster‐RCTs that reported cluster adjusted effect estimates, we extracted the reported effects as risk ratios or hazard ratios. </p> </section> <section id="CD001261-sec-0074"> <h4 class="title">Unit of analysis issues</h4> <p>For trials randomly assigning clusters, we extracted cluster‐adjusted effect estimates when available. We also recorded the number of clusters in the trial, the average size of clusters, the unit of randomization (for example, household or institution) and the statistical methods used to analyse the trial results. For cluster‐RCTs reporting individual patient results without adjustment for clustering, we calculated an intracluster correlation coefficient (ICC) using trial data from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a> (that allowed calculation of unadjusted risk ratios from crude number of individuals and reported cluster‐adjusted hazard ratios) as 0.0015. We calculated the design effect of cluster‐RCTs that did not adjust for clustering taking into account average cluster size. We used this design effect to calculate the effective number of events per control and intervention and the effective number of participants per control and intervention to be used in the meta‐analysis. We present cluster‐unadjusted results in a separate table but do not use them in the meta‐analysis. </p> <p>If a single included trial compared several vaccine arms with a control arm, we labelled the arms separately using a Roman numeral (for example, <a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a> and <a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a>). To avoid including data for controls more than once in the same comparison, we divided the placebo group into equal parts while assuming equal incidence in these groups. </p> </section> <section id="CD001261-sec-0075"> <h4 class="title">Dealing with missing data</h4> <p>When necessary, we contacted the trial authors for clarification or additional details regarding trial methodology or results. In cluster‐RCTs, we asked authors for distribution of outcomes in the different clusters. </p> </section> <section id="CD001261-sec-0076"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by inspecting the forest plots to detect overlapping CIs and the I<sup>2</sup> statistic used to denote levels of heterogeneity as defined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001261-bbs2-0097" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Higgins 2011</a>). </p> <p> <ul id="CD001261-list-0005"> <li> <p>0% to 40% heterogeneity: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD001261-sec-0077"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to inspect funnel plots to assess small study effects and explore the possibility of reporting bias. However, all analyses included too few trials to analyse the funnel plot. </p> </section> <section id="CD001261-sec-0078"> <h4 class="title">Data synthesis</h4> <p>We conducted separate meta‐analyses for each vaccine type. We combined dichotomous data from trials that randomly assigned individuals or corrected numbers from cluster‐RCTs that did not adjust by using risk ratios (RRs) with 95% CIs. In analyses including cluster‐RCTs that reported adjusted risk ratios, we pooled risk ratios from all the trials using inverse variance meta‐analysis. We interpreted the results as efficacy, defined as 1 − RR and expressed as a percentage. We analysed efficacy per year and cumulative efficacy, as they provide different information. Analyses per year show whether the effect of the vaccine decreases over time, and cumulative efficacy demonstrates efficacy overall, for a given period up to three years and longer if available, regardless of whether changes over time occurred within this period. We rounded to the nearest year when trials included follow‐up for only part of a year. The random‐effects model was used throughout the review. We calculated number needed to treat for an additional beneficial outcome (NNTB) (1/reduction in risk of typhoid fever attributable to vaccination) for each type of vaccine based on the cumulative 2.5 to 3‐year point estimate and the incidence of typhoid fever in control groups of trials assessing the given vaccination. </p> </section> <section id="CD001261-sec-0079"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to explore the following potential sources of heterogeneity in subgroup analyses: number of doses; length of follow‐up; type of oral formulation in the Ty21a vaccine (capsules and type of capsule, liquid formulation) and age. However, data were sparse, so we present only the subgroup by type of oral formulation in the meta‐analyses. </p> </section> <section id="CD001261-sec-0080"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses by limiting the meta‐analysis to trials at low of risk of bias due to randomization methods for the primary outcome and assessing whether vaccine efficacy changed. We considered that blinding would not affect bias for our primary outcome of typhoid fever cases, as this measure is objective (<a href="./references#CD001261-bbs2-0112" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. ">Savović 2012</a>). </p> <section id="CD001261-sec-0081"> <h5 class="title">‘Summary of findings' table</h5> <p>We assessed the certainty of the evidence across each outcome measure using the GRADE approach. The certainty rating across studies has one of four levels: high, moderate, low or very low. GRADE initially classifies randomized trials as high certainty, downgrading may be warranted after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias (<a href="./references#CD001261-bbs2-0096" title="GuyattGH , OxmanAD , VistGE , KunzR , Falek‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>). The ‘Summary of findings' tables present the main results of the review and the certainty assessments. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001261-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001261-sec-0082"></div> <section id="CD001261-sec-0083"> <h3 class="title">Description of studies</h3> <section id="CD001261-sec-0084"> <h4 class="title">Results of the search</h4> <p>We present the search results in a PRISMA study flow diagram in <a href="#CD001261-fig-0001">Figure 1</a>. In the previous version of this review, <a href="./references#CD001261-bbs2-0123" title="AnwarE , GoldbergE , FraserA , AcostaCJ , PaulM , LeiboviciL . Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD001261.pub3] ">Anwar 2014</a>, we included 32 publications of 19 trials (the previous version misreported this number, but we have corrected it in the update). We excluded one study that was in the previous review, <a href="./references#CD001261-bbs2-0073" title="ThiemVD , LinFY , SonNH , AnhDD , MaoND , ChuC . The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti‐Vi, and is compatible with routine infant vaccines. Clinical and Vaccine Immunology2011;18(5):730‐5. ">Thiem 2011</a>, due to the refining of the inclusion criteria for adverse events trials. We updated the literature search to 14 February 2018 and identified 50 new unique records. We assessed 13 full‐text articles for eligibility after abstract screening. One new trial met the inclusion criteria (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>), while three trials were ongoing (see the <a href="./references#CD001261-sec-0143" title="">Characteristics of ongoing studies</a> section). </p> <div class="figure" id="CD001261-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001261-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001261-sec-0085"> <h4 class="title">Included studies</h4> <p>In total, 32 records reporting on 19 trials (12 RCTs randomizing individuals and 7 cluster‐RCTs) met the inclusion criteria: see details in <a href="./references#CD001261-sec-0141" title="">Characteristics of included studies</a> table. The 2018 review update includes one new trial evaluating the efficacy of Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi‐TT), PedaTyph (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). </p> <p>All of the trials except <a href="./references#CD001261-bbs2-0005" title="KeitelWA , BondNL , ZahradnikJM , CramtonTA , RobbinsJB . Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine1994;12(3):195‐9. ">Keitel 1994 USA</a> took place in countries where typhoid fever is endemic: Chile (four trials), China (three trials), Vietnam (one trial), Thailand (two trials), Pakistan (one trial), Egypt (one trial), India (two trials), Indonesia (one trial), Nepal (one trial), and South Africa (one trial). None of the trials evaluated vaccine efficacy in travellers from developed countries or compared the efficacy of different types of typhoid vaccines. </p> <p>Participants ranged in age across the trials. Three trials included children aged under 12 years only (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>; <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>), and one trial reported on adults only (<a href="./references#CD001261-bbs2-0008" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella Typhi oral vaccine strain TY21A evaluated in controlled field trials. Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986i CHL</a>). Only three efficacy trials included data on adults over 25 years of age (<a href="./references#CD001261-bbs2-0001" title="AcharyaIL , LoweCU , ThapaR , GurubacharyaVL , ShresthaMB , CadozM , et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. New England Journal of Medicine1987;317(18):1101‐4. ">Acharya 1987 NPL</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0024" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. WangZG , ZhouWZ , ShiJ . Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi1997;18(1):26‐9. ">Wang 1997 CHN</a>). None of the trials reported on use of typhoid vaccination in adults aged over 55 years. Only one trial included children under two years of age (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). All trials either excluded pregnant participants or included no details on their inclusion. </p> <section id="CD001261-sec-0086"> <h5 class="title">Outcomes</h5> <p>Data on the primary outcome, cases of typhoid fever, were derived from 13 trials.</p> <p> <ul id="CD001261-list-0006"> <li> <p>Five trials of Ty21a (<a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a>; <a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a>; <a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a>; <a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a>; <a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a>; <a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a>; <a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a>; <a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>). </p> </li> <li> <p>Six trials of Vi polysaccharide (<a href="./references#CD001261-bbs2-0001" title="AcharyaIL , LoweCU , ThapaR , GurubacharyaVL , ShresthaMB , CadozM , et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. New England Journal of Medicine1987;317(18):1101‐4. ">Acharya 1987 NPL</a>; <a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>; <a href="./references#CD001261-bbs2-0024" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. WangZG , ZhouWZ , ShiJ . Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi1997;18(1):26‐9. ">Wang 1997 CHN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). </p> </li> <li> <p>One Vi‐rEPA trial (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>). </p> </li> <li> <p>One Vi‐TT (PedaTyph) trial (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). </p> </li> </ul> </p> <p>Data on the secondary outcome, adverse events, came from nine trials.</p> <p> <ul id="CD001261-list-0007"> <li> <p>Five trials of Ty21a (<a href="./references#CD001261-bbs2-0008" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella Typhi oral vaccine strain TY21A evaluated in controlled field trials. Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986i CHL</a>; <a href="./references#CD001261-bbs2-0009" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella typhi oral vaccine strain TY21A evaluated in controlled field trials. In: HolmgrenJ , LindbergA , MöllbyR editor(s). Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986ii CHL</a>; <a href="./references#CD001261-bbs2-0018" title="OlanratmaneeT , LevineM , LosonskyG , ThisyakornV , CryzSJJr . Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4‐ to 6‐year‐old Thai children. Journal of Infectious Diseases1992;166(2):451‐2. ">Olanratmanee 1992 THA</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>; <a href="./references#CD001261-bbs2-0023" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980b EGY</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>). </p> </li> <li> <p>Three trials of Vi polysaccharide (<a href="./references#CD001261-bbs2-0005" title="KeitelWA , BondNL , ZahradnikJM , CramtonTA , RobbinsJB . Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine1994;12(3):195‐9. ">Keitel 1994 USA</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>; <a href="./references#CD001261-bbs2-0026" title="ZhouWZ , KooHW , WangXY , ZhangJ , ParkJK , ZhuF , et al. Revaccination with locally‐produced Vi typhoid polysaccharide vaccine among Chinese school‐aged children: safety and immunogenicity findings. Paediatric Infectious Disease Journal2007;26(11):1001‐5. ">Zhou 2007 CHN</a>). </p> </li> <li> <p>One trial of Vi‐rEPA (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>). </p> </li> </ul> </p> <p>One additional individual RCT assessed the Ty21a vaccine and reported on adverse events but did not provide the number of participants per study arm (<a href="./references#CD001261-bbs2-0004" title="CryzSJJr , VanpraparN , ThisyakornU , OlanratmaneeT , LosonskyG , LevineMM , et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infection and Immunity1993;61(3):1149‐51. ">Cryz 1993 THA</a>); therefore we do not include results of this trial in the meta‐analysis. </p> </section> </section> <section id="CD001261-sec-0087"> <h4 class="title">Excluded studies</h4> <p>In this 2018 update we excluded nine trials. Across all versions of this review, we excluded 60 publications (53 trials). For details of excluded trials and reasons for their exclusion, see the <a href="./references#CD001261-sec-0142" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD001261-sec-0088"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD001261-fig-0002">Figure 2</a> for a summary of the ‘Risk of bias' assessment and the <a href="./references#CD001261-sec-0141" title="">Characteristics of included studies</a> for further details on the reasons for review authors' judgements. </p> <div class="figure" id="CD001261-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001261-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001261-sec-0089"> <h4 class="title">Allocation</h4> <p>Six of the 13 trials reporting on efficacy reported low‐risk randomization procedures (<a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>; <a href="./references#CD001261-bbs2-0024" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. WangZG , ZhouWZ , ShiJ . Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi1997;18(1):26‐9. ">Wang 1997 CHN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). The other seven trials did not provide enough information to permit judgement. All but one trial, <a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>, used low‐risk methods to conceal allocation. </p> <p>Three of the 10 trials reporting adverse events described low‐risk randomization procedures (<a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>; <a href="./references#CD001261-bbs2-0026" title="ZhouWZ , KooHW , WangXY , ZhangJ , ParkJK , ZhuF , et al. Revaccination with locally‐produced Vi typhoid polysaccharide vaccine among Chinese school‐aged children: safety and immunogenicity findings. Paediatric Infectious Disease Journal2007;26(11):1001‐5. ">Zhou 2007 CHN</a>). Likewise, three used low‐risk methods to conceal allocation (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). The other trials did not report enough information to permit judgement. </p> </section> <section id="CD001261-sec-0090"> <h4 class="title">Blinding</h4> <p>All but 3 of the 13 trials on clinical efficacy used double‐blinding. Two cluster‐randomized trials could not guarantee blinding of researchers or participants, as they used vaccines that were packaged differently and therefore did not look identical (<a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). However, both trials tried to minimize this effect by assigning each vaccination team to only one vaccine, identifying the vaccines only by code, and not informing local research staff members or participants of the assignment of the code or the vaccine. One cluster‐randomized trial, <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>, was open label with no placebo arm, with the control group having vaccinations as per the normal schedule. There is no information as to whether researchers were blinded. </p> <p>All of the trials that included adverse effects used double‐blinding.</p> </section> <section id="CD001261-sec-0091"> <h4 class="title">Incomplete outcome data</h4> <p>Ten of 13 trials that investigated vaccine efficacy included all randomly assigned participants in the analysis, so we classified them at low risk of attrition bias. Three trials provided no reasons for missing data (<a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a>; <a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a>; <a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a>; <a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a>; <a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a>; <a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a>; <a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a>; <a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a>). </p> <p>We assessed 5 of 10 trials that included adverse events as being at low risk in terms of including all randomly assigned participants in the analysis or providing reasons for missing outcome data. Two trials were unclear on this issue (<a href="./references#CD001261-bbs2-0004" title="CryzSJJr , VanpraparN , ThisyakornU , OlanratmaneeT , LosonskyG , LevineMM , et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infection and Immunity1993;61(3):1149‐51. ">Cryz 1993 THA</a>; <a href="./references#CD001261-bbs2-0008" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella Typhi oral vaccine strain TY21A evaluated in controlled field trials. Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986i CHL</a>; <a href="./references#CD001261-bbs2-0009" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella typhi oral vaccine strain TY21A evaluated in controlled field trials. In: HolmgrenJ , LindbergA , MöllbyR editor(s). Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986ii CHL</a>). We judged the trial that did not provide the number of participants per study arm as being at high risk of attrition bias (<a href="./references#CD001261-bbs2-0004" title="CryzSJJr , VanpraparN , ThisyakornU , OlanratmaneeT , LosonskyG , LevineMM , et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infection and Immunity1993;61(3):1149‐51. ">Cryz 1993 THA</a>). </p> </section> <section id="CD001261-sec-0092"> <h4 class="title">Selective reporting</h4> <p>All but one of the 13 trials on vaccine efficacy reported on pre‐planned outcomes, meriting a classification of low risk of bias. <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a> did not report on paratyphoid outcomes as the prospectively registered protocol had described, so we classified it as being at high risk of bias. The vaccine assessed would not have affected the incidence of <i>S.</i> Paratyphi infections but would have aided us to judge whether the decreased number of infections was due to the effect of the vaccine or consequences of better socioeconomic status of the immunized group (see other sources of bias described below). </p> <p>All 10 trials included in the adverse events analysis reported on plausible outcomes, so we classified them as being at low risk of bias, even though protocols were not available. </p> </section> <section id="CD001261-sec-0093"> <h4 class="title">Other potential sources of bias</h4> <p>Four of the seven cluster‐RCTs on vaccine efficacy provided data on the efficacy of the Ty21a vaccine (<a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a>; <a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a>; <a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>). These four cluster‐RCTs, all of which randomly assigned by classroom, did not adjust for clustering in their results. </p> <p>Two of the vaccine efficacy cluster‐RCTs provided data on the efficacy of the Vi polysaccharide vaccine (<a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). Both of these trials randomly assigned geographic clusters. Study authors provided unpublished cluster‐adjusted data for the meta‐analysis. </p> <p>The remaining vaccine efficacy cluster‐RCT provided data on the efficacy of the Vi‐TT conjugate vaccine PedaTyph (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). The trial cluster‐randomized children by school and did not adjust for clustering in the sample size calculations or in results. The intervention and control groups were different in terms of socioeconomic data, despite randomization, with lower status in the control group. As typhoid fever is associated with poor sanitation and hygiene, it is plausible that the vaccine would prevent more cases in lower socioeconomic groups. Although the authors did not mention it in the published paper, according to the prospectively registered protocol the company who manufactures Peda Typh funded the study. We classified this trial as being at high risk of other sources of bias. </p> </section> </section> <section id="CD001261-sec-0094"> <h3 class="title" id="CD001261-sec-0094">Effects of interventions</h3> <p>See: <a href="./full#CD001261-tbl-0001"><b>Summary of findings for the main comparison</b> Ty21a vaccine (three doses) versus control for preventing typhoid fever</a>; <a href="./full#CD001261-tbl-0002"><b>Summary of findings 2</b> Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</a>; <a href="./full#CD001261-tbl-0003"><b>Summary of findings 3</b> Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</a>; <a href="./full#CD001261-tbl-0004"><b>Summary of findings 4</b> Vi‐TT conjugate vaccine (PedaTyph) (2 doses) versus control for preventing typhoid fever</a> </p> <section id="CD001261-sec-0095"> <h4 class="title">TY21a vaccine</h4> <section id="CD001261-sec-0096"> <h5 class="title">Efficacy</h5> <p>Investigators assessed the TY21a vaccine in one four‐arm individual RCT, <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>, and four cluster‐RCTs, reported in <a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a><a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a><a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a><a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a> and <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>. The cluster‐RCTs did not adjust analyses for the effect of clustering, so they may have overestimated any protective effect. We adjusted results from these trials using an estimated ICC of 0.0015 and average cluster size to calculate the design effect so we could include them in the meta‐analysis. <a href="#CD001261-tbl-0005">Table 1</a> displays adjusted results, and we refer to these findings unless otherwise specified. <a href="#CD001261-tbl-0006">Table 2</a> shows unadjusted results. </p> <div class="table" id="CD001261-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preparation (N doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ICC<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average cluster size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Design effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Typhoid episodes/<br/> participants in intervention group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Typhoid episodes/<br/> participants in in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.10 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.13 to 1.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.11 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.00 to 1.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/20,847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.29 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.18 to 0.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/33,982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/4752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.35 to 1.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.00 to 0.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/35,870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/5338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.13 to 0.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/20,792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.39 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/21,570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.47 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/35,870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/5338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (0.14 to 0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.24 to 0.58)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ICC: intracluster correlation coefficient.<br/> <sup>a</sup>ICC calculated from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>.<br/> <sup>b</sup>Average cluster size for <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> calculated using pilot trial cluster size information. </p> </div> </div> <div class="table" id="CD001261-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a vaccine: unadjusted resultsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preparation (N doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy<sup>c</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Enteric capsules (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.48 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25% (−18% to 52%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.36 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% (−18% to 64%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.47 to 2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4% (−131% to 53%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.56 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−6% (−100% to 44%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.51 to 2.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−17% (−168% to 49%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.55 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24% (−6% to 45%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.65 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15% (−12% to 35%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Enteric capsules (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.29 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52% (21% to 71%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.14 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71% (40% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.33 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26% (−65% to 67%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.42 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19% (−58% to 58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.39 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12% (‐99% to 61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.32 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (34% to 68%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.42 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43% (24% to 58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.10 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71% (14% to 90%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.13 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% (−21% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.11 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67% (5% to 89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (−26% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.00 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (−10% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (−26% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.28 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (9% to 72%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.18 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67% (82% to 37%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.35 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37% (−12% to 65%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (60% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.13 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76% (53% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.39 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31% (−20% to 61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.47 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19% (−39% to 53%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid preparation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (0.13 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77% (61% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative incidence 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.24 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (42% to 76%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: RR: risk ratio; CI: confidence interval.<br/> <sup>a</sup>Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.<br/> <sup>b</sup>Risk ratio with 95% CIs.<br/> <sup>c</sup>Efficacy = 1 − risk ratio. </p> </div> </div> <p>A three‐dose schedule of Ty21a vaccine provided vaccine efficacy of 45% at year 1 (95% CI 14% to 65%; 76,296 participants; <a href="./references#CD001261-fig-0003" title="">Analysis 1.1</a>), 59% at year 2 (95% CI 43% to 71%; 76,296 participants; <a href="./references#CD001261-fig-0004" title="">Analysis 1.2</a>) and 56% at year 3 (95% CI 24% to 75%; 76,296 participants; <a href="./references#CD001261-fig-0005" title="">Analysis 1.3</a>). The cumulative efficacy of the Ty21a vaccine over 2.5 to 3 years was 50% (95% CI 35% to 61%; 235,239 participants; <a href="./references#CD001261-fig-0006" title="">Analysis 1.4</a>). </p> <p>Cumulative efficacy of the three‐dose schedule of Ty21a vaccine for over three years is available from two of the adjusted cluster‐RCTs (<a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a>; <a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a>). Cumulative efficacy was 77% at five years (95% CI 60% to 86%; <a href="#CD001261-tbl-0005">Table 1</a>) and 63% at seven years (95% CI 42% to 76%; <a href="#CD001261-tbl-0005">Table 1</a>). </p> <p>We were unable to conduct subgroup analysis by age, as trials evaluating the efficacy of the Ty21a vaccine did not stratify results according to this variable. </p> <p>In the cumulative analysis there is moderate heterogeneity that is not explained by stratifying results by type of preparation. In direct randomized comparisons between liquid and enteric capsules (<a href="./references#CD001261-fig-0007" title="">Analysis 2.1</a>) and between enteric and gelatin capsules (<a href="./references#CD001261-fig-0008" title="">Analysis 3.1</a>), the heterogeneity was too high to pool the results, so we were unable to conduct a meta‐analysis. </p> </section> <section id="CD001261-sec-0097"> <h5 class="title">Adverse events</h5> <p>None of the individual‐ or cluster‐randomized trials reported any serious adverse events (5 trials, 235,239 participants: <a href="./references#CD001261-bbs2-0008" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella Typhi oral vaccine strain TY21A evaluated in controlled field trials. Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986i CHL</a>; <a href="./references#CD001261-bbs2-0009" title="LevineMM , BlackRE , FerreccioC , ClementsML , LanataC , RooneyJ , et al. The efficacy of attenuated Salmonella typhi oral vaccine strain TY21A evaluated in controlled field trials. In: HolmgrenJ , LindbergA , MöllbyR editor(s). Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference; 1985; Stockholm. Lund, Sweden: Studentlitteratur, 1986:90‐101. ">Levine 1986ii CHL</a>; <a href="./references#CD001261-bbs2-0018" title="OlanratmaneeT , LevineM , LosonskyG , ThisyakornV , CryzSJJr . Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4‐ to 6‐year‐old Thai children. Journal of Infectious Diseases1992;166(2):451‐2. ">Olanratmanee 1992 THA</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>; <a href="./references#CD001261-bbs2-0023" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980b EGY</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./appendices#CD001261-sec-0129">Appendix 2</a>). </p> <p>Compared with placebo, the Ty21a vaccine (both preparations) did not increase the incidence of vomiting (2 trials, 2066 participants; <a href="./references#CD001261-fig-0010" title="">Analysis 4.2</a>), diarrhoea (2 trials, 2066 participants; <a href="./references#CD001261-fig-0011" title="">Analysis 4.3</a>), nausea or abdominal pain (2 trials, 2066 participants; <a href="./references#CD001261-fig-0012" title="">Analysis 4.4</a>), headache (1 trial, 1190 participants; <a href="./references#CD001261-fig-0013" title="">Analysis 4.5</a>), or rash (1 trial, 1190 participants; <a href="./references#CD001261-fig-0014" title="">Analysis 4.6</a>) compared with control. However, fever was more common after vaccine delivery (RR 1.84, 95% CI 1.02 to 3.05; 2 trials, 2066 participants). A pooled analysis of two individual‐RCTs showed a marginal increase in risk of any mild adverse events (RR 1.67, 95% CI 1.03 to 2.72; 2 trials, 1360 participants; <a href="./references#CD001261-fig-0015" title="">Analysis 4.7</a>). </p> <p>The cluster‐randomized studies <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> and <a href="./references#CD001261-bbs2-0023" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980b EGY</a> reported adverse events per dose of vaccine rather than per patient, so we could use these data in the meta‐analysis. There appeared to be more episodes of vomiting and nausea/abdominal pain per dose with the vaccine, but the overall incidence was low (0.1% vomiting with Ty21a versus 0.05% with placebo; 0.03% nausea/abdominal pain with Ty21a versus 0.004% with placebo, <a href="./appendices#CD001261-sec-0129">Appendix 2</a>). </p> <p><a href="./references#CD001261-bbs2-0004" title="CryzSJJr , VanpraparN , ThisyakornU , OlanratmaneeT , LosonskyG , LevineMM , et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infection and Immunity1993;61(3):1149‐51. ">Cryz 1993 THA</a> did not supply the number of participants in the vaccine and placebo groups, so results could not be analysed. Authors noted that all reactions were mild. </p> <p>See <a href="./full#CD001261-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> <section id="CD001261-sec-0098"> <h4 class="title">Vi polysaccharide vaccine</h4> <section id="CD001261-sec-0099"> <h5 class="title">Efficacy</h5> <p>Four individually randomized RCTs assessed the efficacy of this vaccine (<a href="./references#CD001261-bbs2-0001" title="AcharyaIL , LoweCU , ThapaR , GurubacharyaVL , ShresthaMB , CadozM , et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. New England Journal of Medicine1987;317(18):1101‐4. ">Acharya 1987 NPL</a>; <a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>; <a href="./references#CD001261-bbs2-0024" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. WangZG , ZhouWZ , ShiJ . Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi1997;18(1):26‐9. ">Wang 1997 CHN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>), as did two cluster‐RCTs (<a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). We obtained cluster‐adjusted results for efficacy at year 2 following vaccination from the study authors, so we were able to pool the results from the individually randomized RCTs and the cluster‐adjusted RCTs using the generic inverse variance method. </p> <p>The efficacy of the Vi polysaccharide vaccine was 69% at year 1 (95% CI 63% to 74%; 3 trials, 99,797 participants; <a href="./references#CD001261-fig-0016" title="">Analysis 5.1</a>) and 59% at year 2 (95% CI 45% to 69%; 4 trials, 194,969 participants; <a href="./references#CD001261-fig-0016" title="">Analysis 5.1</a>) There was high heterogeneity in year 2 (I<sup>2</sup> = 72%), which we were unable to explain with subgroup analysis. Ty21a efficacy was 50% at year 3 based on a single trial (95% CI 22% to 68%; 11,384 participants; <a href="./references#CD001261-fig-0016" title="">Analysis 5.1</a>). Cumulative efficacy at 2.5 to 3 years, based on the same single trial (<a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>), was 55% (95% CI 30% to 70%; 11,384 participants; <a href="./references#CD001261-fig-0017" title="">Analysis 5.2</a>). </p> <p>Two of the trials used the Widal test (as well as a positive culture) to detect cases of typhoid fever (<a href="./references#CD001261-bbs2-0024" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. WangZG , ZhouWZ , ShiJ . Efficacy and side effects following immunization with Salmonella typhi Vi capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi1997;18(1):26‐9. ">Wang 1997 CHN</a>; <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). Results of the Widal test were not included in the meta‐analysis. Both trials followed participants for six years, and their combined culture‐based results demonstrated that protection was significant in each of the first two years but not in years 3 or 6. Three‐year cumulative efficacy was 69% (95% CI 50% to 81%), and combined efficacy for years 4 through 6 was 11% (95% CI −76% to 55%) (analyses not shown). </p> <p>Three of the RCTs conducted subgroup analysis by age: <a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a> used individual randomization, while <a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a> and <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a> were cluster trials. However, the individually based RCT included very small numbers in each age group (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>); the two cluster‐RCTs did not adjust for clustering and presented their results in the form of hazard ratios rather than risk ratios (with effectiveness of vaccination estimated as: (1 − hazard ratio) × 100% (<a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a>; <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). We were therefore unable to conduct subgroup analysis by age. <a href="#CD001261-tbl-0007">Table 3</a> presents unadjusted results by age from the two cluster‐RCTs. The cluster‐randomized trial conducted in India, <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>, found that two years after vaccination, the Vi polysaccharide vaccine provided significantly more protection than the control condition for children two to five years of age (efficacy 82%, 95% CI 58% to 92%). However, contrary to these results, the cluster‐randomized trial conducted in Pakistan, <a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK,</a> showed no protection among children between two and five years of age compared with placebo at two years after vaccination (efficacy −30%, 95% CI −183% to 40%). </p> <div class="table" id="CD001261-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Efficacy of Vi polysaccharide vaccine: unadjusted cluster‐trial results by agea </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age at baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Typhoid episodes:Vi vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Typhoid episodes:control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Efficacy (95% CI):not adjusted</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cumulative incidence at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to &lt; 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/3154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/3324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−30% (−183% to 40%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/10,084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/10,669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% (9% to 81%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Cumulative incidence at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to &lt; 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/1097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/1095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82% (58% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to &lt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/4282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% (18% to 79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/13,490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/13,125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48% (−44% to 81%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect. </p> </div> </div> </section> <section id="CD001261-sec-0100"> <h5 class="title">Adverse events</h5> <p>No trials reported on serious adverse events.</p> <p>Overall, we did not find a significant difference between vaccine and placebo in the incidence of fever (3 trials, 132,261 participants; <a href="./references#CD001261-fig-0018" title="">Analysis 6.1</a>) or erythema (3 trials, 132,261 participants; <a href="./references#CD001261-fig-0019" title="">Analysis 6.2</a>). However, swelling (RR 6.06, 95% CI 1.07 to 34.22; 3 trials, 1767 participants; <a href="./references#CD001261-fig-0020" title="">Analysis 6.3</a>) and pain at the injection site (RR 7.98, 95% CI 3.69 to 17.24; 1 trial, 667 participants; <a href="./references#CD001261-fig-0021" title="">Analysis 6.4</a>) were more common after delivery of the Vi polysaccharide vaccine. </p> <p>See <a href="./full#CD001261-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> <section id="CD001261-sec-0101"> <h4 class="title">Vi‐rEPA vaccine</h4> <section id="CD001261-sec-0102"> <h5 class="title">Efficacy</h5> <p>One trial in children aged two to five years, conducted in Vietnam, evaluated the efficacy of this vaccine (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>), reporting that it was 94% at year 1 (95% CI 75% to 99%; 12,008 participants; <a href="./references#CD001261-fig-0023" title="">Analysis 7.1</a>) and 87% in year 2 (95% CI 56% to 96%; 12,008 participants; <a href="./references#CD001261-fig-0023" title="">Analysis 7.1</a>), with a two‐year cumulative efficacy of 91% (95% CI 78% to 96%; 12,008 participants; <a href="./references#CD001261-fig-0023" title="">Analysis 7.1</a>). The cumulative efficacy of the Vi‐rEPA vaccine after 3.8 years was 89% (95% CI 77% to 95%; 12,008 participants, <a href="./references#CD001261-fig-0023" title="">Analysis 7.1</a>). The planned vaccine schedule was two doses of vaccine approximately six weeks apart. Although 388 children in the vaccine group received only one dose of vaccine instead of two, authors still analysed them along with those who had received two doses. The cumulative two‐year efficacy for two doses of vaccine was the same as for one or two doses of vaccine, so this did not seem to undermine the validity of the results. </p> <p>No trials assessed the efficacy of this vaccine in children older than five or in adults. </p> </section> <section id="CD001261-sec-0103"> <h5 class="title">Adverse events</h5> <p>One trial evaluated adverse events associated with this vaccine, reporting no serious events (<a href="./references#CD001261-bbs2-0016" title="LanhMN , VanBayP , HoVA , ThanhTC , LinFY , BrylaDA , et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine2003;349(14):1390‐1. LinFY , HoVA , KhiemHB , TrachDD , BayPV , ThanhTC , et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. New England Journal of Medicine2001;344(17):1263‐9. ">Lin 2001 VNM</a>). Fever was more common following delivery of both the first and second vaccinations with Vi‐rEPA compared with placebo (dose 1: RR 2.54, 95% CI 1.69 to 3.82, 12,008 participants, 1 trial, <a href="./references#CD001261-fig-0024" title="">Analysis 8.1</a>; dose 2: RR 4.39, 95% CI 2.85 to 6.77, 11,091 participants, 1 trial, <a href="./references#CD001261-fig-0025" title="">Analysis 8.2</a>). After the first dose of Vi‐rEPA, no participants in either the test or placebo group reported erythema or swelling at the injection site (<a href="./references#CD001261-fig-0026" title="">Analysis 8.3</a>; <a href="./references#CD001261-fig-0028" title="">Analysis 8.5</a>). After the second dose, there was no significant difference between the vaccine and placebo for erythema (<a href="./references#CD001261-fig-0027" title="">Analysis 8.4</a>), but swelling at the injection site was more common in the Vi‐rEPA group (RR 20.15, 95% CI 2.71 to 150.8; 11,091 participants, 1 trial; <a href="./references#CD001261-fig-0029" title="">Analysis 8.6</a>). </p> <p>See <a href="./full#CD001261-tbl-0003">summary of findings Table 3</a>. </p> </section> </section> <section id="CD001261-sec-0104"> <h4 class="title">Vi‐tetanus toxoid conjugated typhoid vaccine (Pedatyph)</h4> <section id="CD001261-sec-0105"> <h5 class="title">Efficacy</h5> <p>One cluster‐randomized trial in children aged six months to 12 years of age assessed the efficacy of this vaccine in India (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). The authors did not adjust for cluster randomization. Using an estimated ICC of 0.0015 (from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>) and an average cluster size of 135, we calculated the design effect as 1.201 and adjusted results accordingly. <a href="#CD001261-tbl-0008">Table 4</a> shows unadjusted results. </p> <div class="table" id="CD001261-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of Vi‐TT (PedaTyph); cluster unadjusted results; year 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of</b> </p> <p><b>doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Vi‐TT (PedaTyph)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio (96% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Efficacy (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.00 to 0.83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (17% to 100%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval.</p> </div> </div> <p>The adjusted efficacy of Vi‐TT (PedaTyph, 2 doses) at one‐year follow‐up was 94% (95% CI −1% to 100%; 1625 participants; <a href="./references#CD001261-fig-0031" title="">Analysis 9.1</a>). </p> </section> <section id="CD001261-sec-0106"> <h5 class="title">Adverse effects</h5> <p>The trial did not report any serious adverse effects.</p> <p>See <a href="./full#CD001261-tbl-0004">summary of findings Table 4</a>. </p> </section> </section> <section id="CD001261-sec-0107"> <h4 class="title">Heterogeneity</h4> <p>Other than where already stated, in most comparisons that included several trials, the degree of heterogeneity was not substantial (that is, I<sup>2</sup> statistic &lt; 50% and Chi<sup>2</sup> test with P value &gt; 0.10). However, because of the limited number of trials included in each comparison, we were unable to identify the reason for the greater degree of heterogeneity in some comparisons. </p> </section> <section id="CD001261-sec-0108"> <h4 class="title">Sensitivity analyses</h4> <p>We performed sensitivity analyses for trials with a split control arm in the main analyses and found that the results did not change (analyses not shown). As most comparisons included few trials, we could not perform sensitivity analyses according to risk of bias. We did not notice any difference in adverse event results from trials that did and did not evaluate efficacy, although we did not undertake formal testing. </p> </section> <section id="CD001261-sec-0109"> <h4 class="title">Number needed to treat for an additional beneficial outcome (NNTB) to prevent one case of typhoid fever </h4> <section id="CD001261-sec-0110"> <h5 class="title">Ty21a vaccine</h5> <p>The liquid formulation of the Ty21a vaccine had a three‐year cumulative protective efficacy of 71% (95% CI 34% to 88%; <a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a>; <a href="./references#CD001261-bbs2-0019" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991i IDN</a>; <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>; <a href="./references#CD001261-fig-0006" title="">Analysis 1.4</a>). The incidence rate in the control group was 544/100,000 with a corresponding NNTB of 259 (95% CI 209 to 541). The enteric capsule formulation of the Ty21a vaccine had three‐year cumulative protective efficacy of 46% (95% CI 32% to 58%; <a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a>; <a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a>; <a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a>; <a href="./references#CD001261-bbs2-0020" title="SimanjuntakCH , PaleologoFP , PunjabiNH , DarmowigotoR , Soeprawoto , TotosudirjoH , et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet1991;338(8774):1055‐9. ">Simanjuntak 1991ii IDN</a>; <a href="./references#CD001261-fig-0006" title="">Analysis 1.4</a>). The incidence in the control group was 734/100,000, and the corresponding NNTB was 296 (95% CI 235 to 426). </p> </section> <section id="CD001261-sec-0111"> <h5 class="title">Vi polysaccharide vaccine</h5> <p>The Vi polysaccharide vaccine has a 2.5‐ to 3‐year cumulative protective efficacy of 55% (95% CI 30% to 70%; <a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>; <a href="./references#CD001261-fig-0010" title="">Analysis 4.2</a>), with an incidence rate of 1160/100,000. From these data, we estimated the NNTB to be 157 (95% CI 1234 to 287). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001261-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001261-sec-0112">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001261-sec-0188">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001261-sec-0112"></div> <section id="CD001261-sec-0113"> <h3 class="title" id="CD001261-sec-0113">Summary of main results</h3> <section id="CD001261-sec-0114"> <h4 class="title">Ty21a vaccine (three doses)</h4> <p>A three‐dose schedule of Ty21a vaccine probably prevents around half of typhoid cases during the first three years after vaccination (moderate‐certainty evidence). These data include patients aged 3 to 44 years. </p> <p>Compared with placebo, this vaccine probably does not cause more vomiting, diarrhoea, nausea, or abdominal pain, (moderate‐certainty evidence) headache, or rash (moderate‐certainty evidence); however, fever is probably more common following vaccination (moderate‐certainty evidence). </p> <p>See <a href="./full#CD001261-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD001261-sec-0115"> <h4 class="title">Vi polysaccharide vaccine (one dose)</h4> <p>A single dose of Vi polysaccharide vaccine prevents around two‐thirds of typhoid cases in the first year after vaccination (high‐certainty evidence). In year 2, trial results were more variable, with the vaccine probably preventing between 45% and 69% of typhoid cases (moderate‐certainty evidence). These data included participants aged 2 to 55 years of age. The three‐year cumulative efficacy of the vaccine may be around 55% (low‐certainty evidence). These data were taken from a single trial conducted in South Africa in the 1980s in participants aged 5 to 15 years. </p> <p>Compared with placebo, this vaccine probably did not increase the incidence of fever (moderate‐certainty evidence) or erythema (low‐certainty evidence); however, swelling (moderate‐certainty evidence) and pain at the injection site (moderate‐certainty evidence) were more common in the vaccine group. </p> <p>See <a href="./full#CD001261-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD001261-sec-0116"> <h4 class="title">Vi‐rEPA vaccine (two doses)</h4> <p>Administration of two doses of the Vi‐rEPA vaccine probably prevents between 50% and 96% of typhoid cases during the first two years after vaccination (moderate‐certainty evidence). These data were taken from a single trial with children two to five years of age conducted in Vietnam. </p> <p>Compared with placebo, both the first and the second dose of this vaccine increased the risk of fever (low‐certainty evidence) and the second dose increased the incidence of swelling at the injection site (moderate‐certainty evidence). </p> <p>See <a href="./full#CD001261-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD001261-sec-0117"> <h4 class="title">Vi‐TT vaccine (two doses)</h4> <p>We are uncertain of the efficacy of administering two doses of Vi‐TT (PedaTyph) in typhoid cases in children during the first year after vaccination (very low‐certainty evidence). These data are taken from a single cluster‐randomized trial in children aged six months to 12 years conducted in India. </p> <p>See <a href="./full#CD001261-tbl-0004">summary of findings Table 4</a>. </p> <p>WIth all vaccines, there were no reported serious adverse effects in RCTs.</p> </section> </section> <section id="CD001261-sec-0118"> <h3 class="title" id="CD001261-sec-0118">Overall completeness and applicability of evidence</h3> <p>In the absence of trials directly comparing different types of typhoid vaccines, we provide an indirect means of comparing the efficacy of different vaccines. The cumulative efficacy at 2.5 to 3 years for the Ty21a vaccine (three doses) and the Vi polysaccharide vaccine was 50% (95% CI 35% to 61%) and 55% (95% CI 30% to 70%), respectively. Both of these vaccines are widely used but are not immunogenic in children under two years old, which is a limitation. A recent systematic review into burden of enteric fever in children found contradictory evidence on the prevalence of typhoid fever in children under the age of five, with a suspected hidden burden, which may be multi‐factorial but includes diagnostic difficulties in this age group (<a href="./references#CD001261-bbs2-0089" title="BrittoC , PollardAJ , VoyseyM , BlohmkeCJ . An appraisal of the clinical features of pediatric enteric fever: systematic review and meta‐analysis of the age‐stratified disease occurrence. Clinical Infectious Diseases2017;64(11):1604‐11. ">Britto 2017</a>). The newer typhoid conjugate vaccines address this gap, as they are suitable to use in children under two years of age. The cumulative efficacy of the Vi‐rEPA vaccine at 3.8 years was higher (89%, 95% CI 76% to 97%), but this vaccine is unlicensed and has not been used commercially. Adverse events were mild in nature and, for the most part, were not significantly different between vaccine and placebo groups. </p> <p>There is information on efficacy in Asia for each of the vaccines. There is limited data on efficacy of typhoid fever vaccination in Africa, with one trial in Egypt for Ty21a, <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a>, and one ViPs trial in South Africa, <a href="./references#CD001261-bbs2-0007" title="KlugmanKP , GilbertsonIT , KoornhofHJ , RobbinsJB , SchneersonR , SchulzD , et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet1987;2(8569):1165‐9. KlugmanKP , KoornhofHJ , RobbinsJB , LeCamNN . Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine1996;14(5):435‐8. ">Klugman 1987 ZAF</a>. There is no information on efficacy of typhoid vaccination in sub‐Saharan Africa. There is evidence on efficacy for Ty21a in South America (<a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a>), but not for any of the other vaccines. </p> <p>The newer typhoid conjugate vaccines Vi‐TT (PedaTyph and Typbar‐TCV) show promise in immunogenicity studies but as of yet efficacy data are only available for PedaTyph (two doses intramuscularly; <a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>). In October 2017, the WHO's strategic advisory group of experts (SAGE) recommended Typbar‐TCV (1 dose intramuscularly; <a href="./references#CD001261-bbs2-0061" title="MohanVK , VaranasiV , SinghA , PasettiMF , LevineMM , VenkatesanR , EllaKM . Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar‐TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2‐cohort, open‐label, double‐blind, randomized controlled phase 3 study. Clinical Infectious Diseases2015;61(3):393‐402. ">Mohan 2015</a>) for children over six months in typhoid endemic countries (<a href="./references#CD001261-bbs2-0122" title="WHO Strategic Advisory Group of Experts (SAGE) on Immunization. Summary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization. October 2017. www.who.int/immunization/policy/sage/SAGE_oct_2017_meeting_summary.pdf?ua=1 (accessed prior to 31 October 2017). ">WHO SAGE 2017</a>), and in 2018 the WHO recommended this vaccine as the preferred choice for adults and children from six months to 44 years of age (<a href="./references#CD001261-bbs2-0120" title="World Health Organization. Tyhoid vaccines: WHO position paper ‐ March 2018. Weekly Epidemiological Record2018; Vol. 93, issue 13:154‐72, Available from: apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1 (last accessed 23 April 2018). ">WHO 2018a</a>). In a human challenge setting Typbar‐TCV demonstrated similar levels of efficacy in healthy adults to ViPS (<a href="./references#CD001261-bbs2-0050" title="JinC , GibaniMM , MooreM , JuelHB , JonesE , MeiringJ , et al. Efficacy and immunogenicity of a Vi‐tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet2017;390(10111):2472‐80. ">Jin 2017</a>), with higher rates of seroconversion and higher antibody GMTs in the conjugate vaccine group. At the time of writing, there were no efficacy data on Typbar‐TCV from field trials. Although promising, it is important to remember that human challenge studies are inherently small. In addition, the bacterial load and the timing of vaccination in relation to the challenge are highly controlled. These studies cannot replace large‐scale real‐life RCTs as sole evidence for approval of new vaccines but could be incorporated into a more efficient approval process. An RCT assessed Typbar‐TCV versus ViPS for immunogenicity and safety in people aged 2 to 45 years old (<a href="./references#CD001261-bbs2-0061" title="MohanVK , VaranasiV , SinghA , PasettiMF , LevineMM , VenkatesanR , EllaKM . Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar‐TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2‐cohort, open‐label, double‐blind, randomized controlled phase 3 study. Clinical Infectious Diseases2015;61(3):393‐402. ">Mohan 2015</a>). Infants and children aged 6 to 23 months were observed in a non‐controlled parallel trial. As there was no placebo control group, the trial could not assess adverse events from Typbar‐TCV, but these were reported as similar with TCV and ViPs, fever being the most common, with a single serious adverse event deemed unrelated to the vaccine. In an observational group of children under two years in the same study, authors again described adverse events as uncommon, with fever being the most usual (<a href="./references#CD001261-bbs2-0061" title="MohanVK , VaranasiV , SinghA , PasettiMF , LevineMM , VenkatesanR , EllaKM . Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar‐TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2‐cohort, open‐label, double‐blind, randomized controlled phase 3 study. Clinical Infectious Diseases2015;61(3):393‐402. ">Mohan 2015</a>). </p> <p>From the evidence available we cannot comment on vaccine herd protection. As typhoid fever is spread faeco‐orally through contaminated food and water, it is plausible that if endemic populations began to routinely use the vaccines, intensity of transmission would be reduced due to a subsection of the population who were protected against infection (<a href="./references#CD001261-bbs2-0090" title="ClemensJ , ShinS , AliM . New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infectious Diseases2011;11(6):482‐7. ">Clemens 2011</a>). However, we did not find any studies describing the effect of vaccination on disease burden in the rest of the community. </p> </section> <section id="CD001261-sec-0119"> <h3 class="title" id="CD001261-sec-0119">Quality of the evidence</h3> <p>We assessed the certainty of evidence provided by the randomized studies using the GRADE approach, presenting our assessments in <a href="./full#CD001261-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD001261-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD001261-tbl-0003">summary of findings Table 3</a>, and <a href="./full#CD001261-tbl-0004">summary of findings Table 4</a>. </p> <p>For the most widely used vaccines, oral Ty21a and ViPS, the evidence of benefit is of moderate certainty. A main limitation for us with Ty21a was the lack of cluster adjustment in trials using this method. For our meta‐analysis we estimated the effect of clustering, extrapolating from a ViPs trial where clustering was taken into account. For this reason we downgraded certainty to moderate. Although there is moderate unexplained heterogeneity in the 2.5 to 3 year cumulative efficacy of Ty21a, the CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically significant. </p> <p>For ViPs the certainty of evidence for efficacy in year 1 was high, but we downgraded it to moderate in the second year due to unexplained heterogeneity. Efficacy in year 3 and the 2.5‐year cumulative efficacy was low, but only one trial assessed longer follow‐up in South Africa in children aged 5 to 15. There was also imprecision as CIs were wide for both of these results. </p> <p>The certainty of evidence for Vi‐rEPA was moderate, as there was a single trial, in one location (Vietnam) and only in children aged two to five. </p> <p>Certainty of evidence for the new Vi‐TT vaccine is too limited to clearly make a recommendation for its adoption. The certainty of evidence for Vi‐TT (PedaTyph) is very low. There was lack of adjustment for cluster‐randomization and a risk of bias (funding by vaccine manufacturer, differing socioeconomic status between vaccine and control group, and selective outcome reporting). As the efficacy data is limited to one trial in children aged six months to 12 years in one location in India, we also downgraded the certainty of evidence for indirectness. The longer‐term protection for PedaTyph is still unknown, as only one‐year follow‐up data are available. </p> <p>There were no serious adverse events reported for any of the vaccines, so we could not assess certainty of evidence. </p> </section> <section id="CD001261-sec-0120"> <h3 class="title" id="CD001261-sec-0120">Potential biases in the review process</h3> <p>We estimated an ICC for unadjusted cluster‐randomized trials that might not be precise. We did not conduct sensitivity analyses for the ICC, but we took a conservative approach and believe that the estimates are reasonable. </p> <p>Diagnosis of typhoid fever remains a challenge, which may have affected the trial results for all of the vaccines. Our analysis for vaccine efficacy relies on blood‐culture positive typhoid fever; typhoid fever cases that are blood culture negative were missed. In one study the sensitivity of blood cultures compared to bone marrow cultures was only 66% (<a href="./references#CD001261-bbs2-0105" title="MogasaleV , MaskeryB , OchiaiRL , LeeJS , MogasaleVV , RamaniE , et al. Burden of typhoid fever in low‐income and middle‐income countries: a systematic, literature‐based update with risk‐factor adjustment. Lancet Global Health2014;2(10):e570‐80. ">Mogasale 2014</a>). However, all of the trials that we included used positive blood culture for diagnosis of typhoid fever, and we did not exclude any trials on this basis of the efficacy outcome definition alone. Thus, we have presented the evidence as completely as possible. </p> <p>None of the vaccines identified protect against <i>S.</i> Paratyphi A, the other ‘typhoidal' serovar of <i>Salmonella,</i> and most vaccine trials did not include outcomes for incidence of paratyphoid fever. Thus results reflect efficacy against typhoid fever caused by<i>S.</i> Typhi alone and do not reflect the overall efficacy against the disease in locations where <i>S.</i> Paratyphi<i>A</i> causes a significant number of cases. </p> <p>We excluded human challenge studies as the bacterial inoculum in challenge trials is much higher and the timing of infection relative to vaccination is highly controlled compared to the real life situation, meaning the effect in real life is more difficult to extrapolate.This could have introduced bias against this vaccine because we had fewer data available for some of the newer vaccines, as human challenge studies provide results in a more time‐ and cost‐efficient manner compared to large scale implementation in RCTs. We are examining the methodological aspects of this approach of evaluating vaccines and how best to assess and present human challenge studies. </p> </section> <section id="CD001261-sec-0121"> <h3 class="title" id="CD001261-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>No other systematic reviews were identified since the last publication of this review in 2014. </p> <p>WHO recommends ViPS in people over two years old and oral Ty21a enteric capsules in people over six in areas with endemic typhoid fever and for outbreak control. This review provides evidence in support of this recommendation. The WHO recommends Vi‐TT Typbar‐TCV for infants and children over six months old in typhoid endemic with catch‐up vaccination where feasible (<a href="./references#CD001261-bbs2-0120" title="World Health Organization. Tyhoid vaccines: WHO position paper ‐ March 2018. Weekly Epidemiological Record2018; Vol. 93, issue 13:154‐72, Available from: apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1 (last accessed 23 April 2018). ">WHO 2018a</a>). This review does not provide evidence for this recommendation, but it is likely that updates will when the ongoing studies investigating Vi‐TT Tybar‐TCV are completed (<a href="./references#CD001261-bbs2-0083" title="ISRCTN11643110 . TyVAC Bangladesh: Typhoid Vaccine Trial [Assessing the impact of a Vi‐Polysaccharide Conjugate Vaccine in preventing typhoid infection among Bangladeshi children – a Phase IV trial]. isrctn.com/ISRCTN11643110 (first received 5 February 2018). ">ISRCTN11643110</a>; <a href="./references#CD001261-bbs2-0084" title="ISRCTN43385161 . TyVAC Nepal: typhoid vaccine study [Assessing the impact of a Vi‐Polysaccharide Conjugate Vaccine in preventing typhoid infection among Nepalese children – a Phase III trial]. isrctn.com/ISRCTN43385161 (first received 20 June 2017). ">ISRCTN43385161</a>; <a href="./references#CD001261-bbs2-0085" title="NCT03299426 . Clinical efficacy of typhoid conjugate vaccine (Vi‐TCV) among children age 9 months through 12 years in Blantyre, Malawi [A Phase III Randomized, Double‐Blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine (Vi‐TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi]. clinicaltrials.gov/show/NCT03299426 (first received 3 October 2017). ">NCT03299426</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001261-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001261-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001261-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, year 1." data-id="CD001261-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, year 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 2 Incidence of typhoid fever, year 2." data-id="CD001261-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 2 Incidence of typhoid fever, year 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 3 Incidence of typhoid fever, year 3." data-id="CD001261-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 3 Incidence of typhoid fever, year 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 4 Cumulative incidence of typhoid fever at 2.5 to 3 years." data-id="CD001261-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ty21a vaccine (3 doses) versus control: efficacy, Outcome 4 Cumulative incidence of typhoid fever at 2.5 to 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ty21a vaccine: liquid formulation versus enteric capsules (3 doses), Outcome 1 Cumulative incidence of typhoid fever at 2.5 to 3 years." data-id="CD001261-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Ty21a vaccine: liquid formulation versus enteric capsules (3 doses), Outcome 1 Cumulative incidence of typhoid fever at 2.5 to 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years, Outcome 1 Incidence of typhoid fever." data-id="CD001261-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years, Outcome 1 Incidence of typhoid fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 1 Fever." data-id="CD001261-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 1 Fever.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 2 Vomiting." data-id="CD001261-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 2 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 3 Diarrhoea." data-id="CD001261-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 3 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 4 Nausea or abdominal pain." data-id="CD001261-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 4 Nausea or abdominal pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 5 Headache." data-id="CD001261-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 5 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 6 Rash." data-id="CD001261-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 6 Rash.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 7 Any mild adverse event." data-id="CD001261-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Ty21a vaccine versus control: adverse events, Outcome 7 Any mild adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 1 Incidence of typhoid fever." data-id="CD001261-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 1 Incidence of typhoid fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 2 Cumulative incidence of typhoid fever at 2.5 to 3 years." data-id="CD001261-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Vi polysaccharide vaccine (1 dose) versus control: efficacy, Outcome 2 Cumulative incidence of typhoid fever at 2.5 to 3 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 1 Fever." data-id="CD001261-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 1 Fever.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 2 Erythema." data-id="CD001261-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 2 Erythema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 3 Swelling at injection site." data-id="CD001261-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 3 Swelling at injection site. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 4 Pain at injection site." data-id="CD001261-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 4 Pain at injection site. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 5 Serious adverse events." data-id="CD001261-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Vi polysaccharide vaccine versus control: adverse events, Outcome 5 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Vi‐rEPA (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever." data-id="CD001261-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Vi‐rEPA (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 1 Fever after Vi‐rEPA (dose1)." data-id="CD001261-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 1 Fever after Vi‐rEPA (dose1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 2 Fever after Vi‐rEPA (dose 2)." data-id="CD001261-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 2 Fever after Vi‐rEPA (dose 2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 3 Erythema after Vi‐rEPA (dose 1)." data-id="CD001261-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 3 Erythema after Vi‐rEPA (dose 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 4 Erythema after Vi‐rEPA (dose 2)." data-id="CD001261-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 4 Erythema after Vi‐rEPA (dose 2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 5 Swelling at injection site after Vi‐rEPA (dose 1)." data-id="CD001261-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 5 Swelling at injection site after Vi‐rEPA (dose 1). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 6 Swelling at injection site after Vi‐rEPA (dose 2)." data-id="CD001261-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 6 Swelling at injection site after Vi‐rEPA (dose 2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 7 Serious adverse events." data-id="CD001261-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Vi‐rEPA vaccine versus control: adverse events, Outcome 7 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001261-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/urn:x-wiley:14651858:media:CD001261:CD001261-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_t/tCD001261-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, Year 1." data-id="CD001261-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacy, Outcome 1 Incidence of typhoid fever, Year 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/media/CDSR/CD001261/image_n/nCD001261-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001261-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ty21a vaccine (three doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ty21a vaccination (three doses) versus placebo for typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults and children aged 5 years of age and older </p> <p><b>Settings</b>: any </p> <p><b>Intervention</b>: oral Ty21a (3 doses) ‐ liquid, enteric capsule, or gelatin capsule </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ty21a (3 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 1</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.55</b> (0.35 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 10,000</b><br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b> (0.29 to 0.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,e</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 2) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 10,000</b><br/> (17 to 34) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cases of typhoid fever,</b> </p> <p><b>Year 3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.44</b> (0.25 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76,296<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,e</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (1 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 10,000</b><br/> (15 to 45) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2.5 to 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.50</b> (0.39 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235,239<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,d,f</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Cases of typhoid fever are probably reduced with vaccination</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b><br/> (2 to 3) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐ risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 10,000</b><br/> (23 to 38) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The incidence of typhoid in a medium ‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>).The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No serious risk of bias detected.<br/> <sup>b</sup>No serious indirectness detected: studies based in Chile, Indonesia, and Egypt.<br/> <sup>c</sup>No serious inconsistency I<sup>2</sup> = 33%.<br/> <sup>d</sup>Downgraded for imprecision: cluster‐adjusted trials added, estimated ICC = 0.0015 (from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>).<br/> <sup>e</sup>No serious inconsistency, no heterogeneity I<sup>2</sup> = 0%.<br/> <sup>f</sup>There is moderate heterogeneity (I<sup>2</sup> = 50%), which is not explained by stratifying into type of preparation. However, the CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically significant, so we have not downgraded for this. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ty21a vaccine (three doses) versus control for preventing typhoid fever</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001261-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults and children of 2 years of age and older<br/> <b>Settings</b> : any<br/> <b>Intervention</b> : Vi polysaccharide vaccine (1 dose)<br/> <b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi polysaccharide vaccine (1 dose)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 1</b><br/> Blood culture </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.31</b> <br/> (0.26 to 0.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>99,797<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>b,c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.2 per 10,000</b><br/> (1.0 to 1.5) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18.29 per 10,000</b><br/> (15.34 to 21.83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b><br/> (0.31 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>194,969<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,f,g,e</sup> </p> <p>Due to inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.6 per 10,000</b><br/> (1.2 to 2.2) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24.19 per 10,000</b><br/> (18.29 to 32.45) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>I<b>ncidence of typhoid fever</b> –<b>year 3</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.5</b> </p> <p>(0.32 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>11,384</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>h,i</sup> </p> <p>Due to imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>May reduce incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 10,000</b> </p> <p>(1.28 to 3.12)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29.5 per 10,000</b> </p> <p>(18.88 to 46.02)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2.5 to 3 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> (0.30 to 0.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>11,384</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>h,i</sup> </p> <p>Due to imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>May reduce incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1.8 per 10,000</b> </p> <p>(1.2 to 2.8)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26.55 per 10,000</b> (17.7 to 41.3) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No serious adverse events reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> <p>(4.2 to 5.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.84 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132,261<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,c,k,l</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably little or no association with fever</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/> (2 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b> <br/> (0.33 to 4.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132,261<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>b,j,l</sup> </p> <p>Due to imprecision and inconsistency</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have little or no association with erythema</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>).The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <sup>b</sup>No serious risk of bias detected.<br/> <sup>c</sup>No serious inconsistency: The result was consistent across all 3 trials (I<sup>2</sup> = 0%).<br/> <sup>d</sup>No serious indirectness: the vaccine has been evaluated in trials from Nepal, South Africa and China. Of note, none of the trials were conducted in travellers from nonendemic settings, and all three trials excluded children younger than 2 years of age and pregnant women.<br/> <sup>e</sup>No serious imprecision: the result is statistically significant with a narrow 95% CI. The meta‐analysis is adequately powered to detect this effect.<br/> <sup>f</sup>Downgraded by 1 level for inconsistency: the magnitude of the protective effect varied between trials from 34% to 69% (I<sup>2</sup> = 72%). The reasons for this are not clear; one potential factor may be the different age groups included in the trials, with <a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a> suggesting lower protective effect in children &lt; 5 years of age.<br/> <sup>g</sup>No serious indirectness: the vaccine has been evaluated in trials from endemic settings (India, Pakistan, China and South Africa).<br/> <sup>h</sup>Downgraded by 1 level for imprecision: wide CIs.<br/> <sup>i</sup>Downgraded by 1 level for indirectness ‐ only assessed in one trial in South Africa in children aged 5 to 15 years.<br/> <sup>k</sup>No serious indirectness: the vaccine has been evaluated in trials from endemic settings (China) and in one trial conducted in a non‐endemic setting (USA).<br/> <sup>l</sup>Downgraded by 1 level for serious imprecision: The result is not statistically significant.<br/> <sup>j</sup>Downgraded by 1 level for inconsistency (I<sup>2</sup> = 63%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001261-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults and children of 2 years of age and older<br/> <b>Settings</b> : any<br/> <b>Intervention</b> : Vi‐rEPA vaccine (2 doses)<br/> <b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi‐rEPA vaccine (2 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 1</b><br/> Follow‐up: 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.06</b> <br/> (0.01 to 0.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b,c</sup> </p> <p>Due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.24 per 10,000</b><br/> (0.04 to 1) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3.5 per 10,000</b><br/> (0.6 to 14.8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of typhoid fever</b> – <b>year 2</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.13</b> <br/> (0.04 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.52 per 10,000</b><br/> (0.16 to 1.8) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7.7 per 10,000</b><br/> (2.4 to 26.0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 2 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.09</b> (0.04 to 0.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.36 per 10,000</b> (0.16 to 0.88) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5.31 per 10,000</b> (2.36 to 12.98) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cumulative cases of typhoid fever at 3.8 years</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> (0.05 to 0.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12,008</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> <p>Due to indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Probably reduces incidence of typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.44 per 10,000</b> (0.2 to 0.92) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 10,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6.49 per 10,000</b> </p> <p>(2.95 to 13.57)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after Vi‐rEPA (dose1)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(8 to 18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.54</b> <br/> (1.69 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,008<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with fever following vaccination</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fever after Vi‐rEPA (dose2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> <p>(11 to 27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.39</b> </p> <p>(2.85 to 6.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with fever following vaccination</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Erythema after Vi‐rEPA (dose 2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.4 per 1000</b> </p> <p>(0.04 to 4.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.01</b> <br/> (0.19 to 22.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> <p>Due to serious imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May have little or no association with erythema</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Swelling at injection site after Vi‐rEPA (dose 2)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0.2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> <p>(0.5 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 20.15</b> <br/> (2.71 to 150.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,091<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> <p>Due to imprecision</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probably associated with swelling at injection site</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The incidence of typhoid in a medium‐risk setting is taken from the control group in a study from China (<a href="./references#CD001261-bbs2-0025" title="AcostaCJ , Hong‐HuiY , NingW , QionG , QunD , XiaoleiM , et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow‐up. Vaccine2005;23(48‐9):5618‐23. YangHH , WuCG , XieGZ , GuQW , WangBR , WangLY , et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south‐western China. Bulletin of the World Health Organization2001;79(7):625‐31. ">Yang 2001 CHN</a>). The incidence of typhoid in a high‐risk setting is taken from a study in India (<a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>). This is consistent with the incidence levels described by a global epidemiological study (<a href="./references#CD001261-bbs2-0091" title="CrumpJA , LubySP , MintzED . The global burden of typhoid fever. Bulletin of the World Health Organization2004;82(5):346‐53. ">Crump 2004</a>).<br/> <sup>b</sup>No serious risk of bias detected.<br/> <sup>c</sup>Downgraded by 1 level for indirectness: the vaccine has been evaluated by only one trial in children 2 to 5 years of age in a high‐incidence setting (Vietnam).<br/> <sup>d</sup>Downgraded by 1 level for imprecision: wide 95% CIs.<br/> <sup>e</sup>Downgraded by 1 level for serious imprecision: the result is not statistically significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Vi‐rEPA vaccine (2 doses) versus control for preventing typhoid fever</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001261-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Vi‐TT conjugate vaccine (PedaTyph) (2 doses) versus control for preventing typhoid fever</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vi‐TT conjugate vaccine versus control for preventing typhoid fever</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children aged 6 months to 12 years </p> <p><b>Settings</b> : India<br/> <b>Intervention</b>: Vi‐TT (PedaTyph) vaccine (2 doses) </p> <p><b>Comparison</b>: control; efficacy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control; efficacy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vi‐TT conjugate; (2 doses)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of typhoid fever – year 1</p> <p>Follow‐up: 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0.8 per 1000</p> <p>(0 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.06<sup>b</sup> </p> <p>(0.00 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1625<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c,d,e</sup> </p> <p>Due to risk of bias, serious imprecision and indirectness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if this vaccine prevents typhoid fever</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI</b> : confidence interval; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The basis for the assumed risk is taken from the disease incidence in the control group in the trial (<a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a>).<br/> <sup>b</sup>Primary trial is not cluster‐adjusted. This estimate uses a small assumed intracluster correlation coefficient of 0.0015 calculated from cluster‐randomized ViPs vaccine trial <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>, which did adjust for clustering.<br/> <sup>c</sup>Downgraded by 1 level for risk of bias.<br/> <sup>d</sup>Downgraded by 1 level for imprecision. Wide CIs that include appreciable harm and few (11 events) in the trial.<br/> <sup>e</sup>Downgraded by 1 level for indirectness. Only one trial in one setting and in children under 12 years. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Vi‐TT conjugate vaccine (PedaTyph) (2 doses) versus control for preventing typhoid fever</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001261-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preparation (N doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ICC<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Average cluster size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Design effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Typhoid episodes/<br/> participants in intervention group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Typhoid episodes/<br/> participants in in control group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.10 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.13 to 1.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.11 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.00 to 1.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/20,847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.29 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (0.18 to 0.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/33,982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/4752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.35 to 1.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/13,980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/15,087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.00 to 0.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/35,870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/5338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.13 to 0.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/20,792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.39 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/21,570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/5279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.47 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/35,870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/5338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (0.14 to 0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence</p> <p>7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/21,400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/5286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37 (0.24 to 0.58)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ICC: intracluster correlation coefficient.<br/> <sup>a</sup>ICC calculated from <a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a>.<br/> <sup>b</sup>Average cluster size for <a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> calculated using pilot trial cluster size information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001261-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a vaccine: unadjusted resultsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Preparation (N doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy<sup>c</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001261-bbs2-0003" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric‐coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. ">Black 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Enteric capsules (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.48 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25% (−18% to 52%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.36 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% (−18% to 64%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (0.47 to 2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4% (−131% to 53%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.56 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−6% (−100% to 44%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 (0.51 to 2.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−17% (−168% to 49%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76 (0.55 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24% (−6% to 45%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.65 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15% (−12% to 35%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001261-bbs2-0002" title="BlackRE , LevineMM , FerreccioC , ClementsML , LanataC , RooneyJ , et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric coated capsules in a controlled field trial. Vaccine1990;8(1):81‐4. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. ">Black 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>Enteric capsules (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.29 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52% (21% to 71%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.14 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71% (40% to 86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.33 to 1.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26% (−65% to 67%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.42 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19% (−58% to 58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.39 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12% (‐99% to 61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.32 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54% (34% to 68%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.42 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43% (24% to 58%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (0.10 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71% (14% to 90%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.13 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60% (−21% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.11 to 0.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67% (5% to 89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (−26% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (0.00 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (−10% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (0.00 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93% (−26% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0010" title="GermanierR , LevineMM . The live oral typhoid vaccine Ty21a: recent field trial results. Collana Monografica1986;3(1‐2):19‐22. LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , BlackRE , GermanierR . Large‐scale field trial of Ty21a live oral typhoid vaccine in enteric‐coated capsule formulation. Lancet1987;1(8541):1049‐52. LevineMM , FerreccioC , BlackRE , LagosR , San MartinO , BlackwelderWC . Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical Infectious Diseases2007;45(Suppl 1):S24‐28. LevineMM , TacketCO , HerringtonD , LosonskyG , MurphyJ , FerreccioC . The current status of typhoid vaccine development and clinical trials with typhoid vaccines. Southeast Asian Journal of Tropical Medicine and Public Health1988;19(3):459‐69. LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (0.28 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49% (9% to 72%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.18 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67% (82% to 37%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0015" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.35 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37% (−12% to 65%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0022" title="WahdanMH , SériéC , CerisierY , SallamS , GermanierR . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three‐year results. Journal of Infectious Diseases1982;145(3):292‐5. WahdanMH , SériéC , GermanierR , LackanyA , CerisierY , GuerinN , et al. A controlled field trial of live oral typhoid vaccine Ty21a. Bulletin of the World Health Organization1980;58(3):469‐74. ">Wahdan 1980a EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98% (60% to 100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid formulation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (0.13 to 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76% (53% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0012" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69 (0.39 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31% (−20% to 61%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0013" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987iv CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 2.5 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gelatin capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81 (0.47 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19% (−39% to 53%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0014" title="LevineMM , FerreccioC , AbregoP , MartinOS , OrtizE , CryzS . Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):22‐7. LevineMM , FerreccioC , CryzS , OrtizE . Comparison of enteric‐coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet1990;336(8720):891‐4. ">Levine 1990i CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative incidence 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liquid preparation (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (0.13 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77% (61% to 87%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001261-bbs2-0011" title="LevineMM , TaylorDN , FerreccioC . Typhoid vaccines come of age. Pediatric Infectious Disease Journal1989;8(6):374‐81. ">Levine 1987ii CHL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative incidence 7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enteric capsules (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.24 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63% (42% to 76%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Abbreviations: RR: risk ratio; CI: confidence interval.<br/> <sup>a</sup>Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.<br/> <sup>b</sup>Risk ratio with 95% CIs.<br/> <sup>c</sup>Efficacy = 1 − risk ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Cluster‐randomized trials: efficacy of oral Ty21a vaccine: unadjusted resultsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001261-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Efficacy of Vi polysaccharide vaccine: unadjusted cluster‐trial results by agea </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age at baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Typhoid episodes:Vi vaccine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Typhoid episodes:control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Efficacy (95% CI):not adjusted</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001261-bbs2-0006" title="KhanI , SoofiS , OchiaiR , HabibM , SahitoS , NizamiS , et al. Effectiveness of Vi capsular polysaccharide vaccine among children: a cluster randomised trial in Karachi, Pakistan. Vaccine2012;30(36):5389‐95. ">Khan 2012 PAK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cumulative incidence at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to &lt; 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/3154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/3324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−30% (−183% to 40%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/10,084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/10,669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% (9% to 81%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001261-bbs2-0021" title="SurD , OchiaiRL , BhattacharyaSK , GangulyNK , AliM , MannaB , et al. A cluster‐randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine2009;361(4):335‐44. ">Sur 2009 IND</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Cumulative incidence at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to &lt; 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/1097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/1095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82% (58% to 92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to &lt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/4282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54/4584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59% (18% to 79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/13,490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/13,125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48% (−44% to 81%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Efficacy of Vi polysaccharide vaccine: unadjusted cluster‐trial results by agea </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001261-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of Vi‐TT (PedaTyph); cluster unadjusted results; year 1</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of</b> </p> <p><b>doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Vi‐TT (PedaTyph)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk ratio (96% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Efficacy (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001261-bbs2-0017" title="MitraM , ShahN , GhoshA , ChatterjeeS , KaurI , BhattacharyaN , et al. Efficacy and safety of vi‐tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Human Vaccines &amp; Immunotherapeutics2016;12(4):939‐45. ">Mitra 2016 IND</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.00 to 0.83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (17% to 100%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Efficacy of Vi‐TT (PedaTyph); cluster unadjusted results; year 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/full#CD001261-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ty21a vaccine (3 doses) versus control: efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of typhoid fever, year 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of typhoid fever, year 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.29, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of typhoid fever, year 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.25, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cumulative incidence of typhoid fever at 2.5 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.39, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ty21a vaccine (3 doses) versus control: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ty21a vaccine: liquid formulation versus enteric capsules (3 doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cumulative incidence of typhoid fever at 2.5 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.24, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ty21a vaccine: liquid formulation versus enteric capsules (3 doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of typhoid fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Ty21a vaccine versus control: adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.02, 3.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.43, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.52, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Nausea or abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Enteric capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [1.53, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Liquid formulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.90, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 In milk with sodium bicarbonate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.39, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.76, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.61, 14.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Any mild adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.03, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Ty21a vaccine versus control: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vi polysaccharide vaccine (1 dose) versus control: efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of typhoid fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Year 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.26, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Year 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.31, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Year 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.32, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cumulative incidence of typhoid fever at 2.5 to 3 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.30, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vi polysaccharide vaccine (1 dose) versus control: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Vi polysaccharide vaccine versus control: adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Erythema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [0.45, 20.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Swelling at injection site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1767</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.06 [1.07, 34.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pain at injection site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.98 [3.69, 17.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Vi polysaccharide vaccine versus control: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Vi‐rEPA (2 doses) versus control: efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of typhoid fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Year 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Year 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.04, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cumulative 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.04, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Cumulative 46 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.05, 0.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Vi‐rEPA (2 doses) versus control: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Vi‐rEPA vaccine versus control: adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fever after Vi‐rEPA (dose1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.69, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fever after Vi‐rEPA (dose 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.39 [2.85, 6.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Erythema after Vi‐rEPA (dose 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Erythema after Vi‐rEPA (dose 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.18, 22.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Swelling at injection site after Vi‐rEPA (dose 1) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Swelling at injection site after Vi‐rEPA (dose 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.15 [2.71, 150.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Vi‐rEPA vaccine versus control: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001261-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of typhoid fever, Year 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Vi‐TT vaccine Peda Typh (2 doses) versus control: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001261.pub4/references#CD001261-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001261.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001261-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001261-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001261-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001261-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001261-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001261-note-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001261-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001261\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001261\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001261\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001261\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001261\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001261.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001261.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001261.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001261.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001261.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719069717"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001261.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719069721"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001261.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddfc16dfb1be4',t:'MTc0MDcxOTA3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 